Note: Descriptions are shown in the official language in which they were submitted.
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
1
Compositions And Methods For Increasing Iron Intake in a Mammal
Cross-Reference to Related Applications
This application claims priority to US provisional application no. 62/146,897,
filed
April 13, 2015, and GB patent application no. 1416293.7, filed September 15,
2014, the
contents of which are incorporated herein by reference.
Technical Field
The invention relates to compositions suitable for delivering iron to a
mammal.
Background to the Invention
Oral iron is often poorly absorbed and tolerated in mammals, and according to
the
World Health Organisation (WHO) iron deficiency affects more than two billion
people in
developed and developing countries. This can result in adverse effects on
cognitive function,
oxygen transport, metabolism and immune function.
Iron is predominantly supplemented orally as the ferrous (Fe 2+) iron, which
is
absorbed actively in response to body need through the divalent metal
transporter 1 (DMT-
1), yet has poor oral bioavailability and tolerability. Ferric (Fe 3+) iron is
usually better
tolerated from a gastrointestinal point of view but tends to have poorer
bioavailability than
ferrous iron. Ferrous sulfate continues to be recommended by the WHO as the
preferred
form of iron for oral administration. Delayed release and/or gastroprotective
formulations
(for example enteric coated) with and without iron have been marketed but are
long
acknowledged to persons known in the art to be less bioavailable and,
accordingly, are not
recommended. See, e.g., Walker S., et al., "Bioavailability of iron in oral
ferrous sulfate
preparations in healthy volunteers," Canadian Medical Association Journal
1989; (141): 543-
547. Current forms of oral iron used for supplementation have significant
limitations,
helping to explain the high incidence of iron deficiency, the only nutritional
deficiency
prevalent in developing and developed countries.
Summary of the Invention
One embodiment of the invention is a composition comprising iron and a carrier
comprising denatured protein, wherein the composition releases less than 70%
or less than
50 wt% of the total iron content as ferrous iron over the course of one hour
in simulated
gastric fluid at pH 1.6, and wherein the composition, when administered orally
to a human,
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
2
has a relative bioavailability of at least 120% that of an equimolar dose of
an orally
administered solution of ferrous sulfate in acidified water.
In one embodiment, the composition has an iron: protein ratio, by weight, of
1:500
to 1:5.
In one embodiment, the composition is largely amorphous.
In one embodiment, the denatured protein is at least 50%, 80% or 90%
denatured.
In one embodiment, the denatured protein contains at least 50%, 80% or 90%
denatured beta lactoglobulin.
In one embodiment, the moisture content of the composition is less than 10 %
by
weight.
In one embodiment, the carrier comprises a core and a skin, wherein skin
comprises
a denatured aggregated protein. Optionally, the skin further comprises a
gelling agent.
In one embodiment, the core comprises a denatured aggregated protein matrix.
Optionally, the denatured protein contains, excluding iron, less than 1%
divalent metal ions
(w/v).
In one embodiment, the composition, when administered orally to a human, has a
relative bioavailability of at least 130%, 140% or 150% that of an equimolar
dose of an orally
administered solution of ferrous sulfate in acidified water.
In one embodiment, the composition releases less than 50 wt% of the total iron
content as ferrous iron over the course of 30 minutes in simulated gastric
fluid at pH 1.6; the
composition releases less than 20 wt% of the total iron content as ferrous
iron over the
course of 30 minutes in simulated gastric fluid at pH 1.6; the composition
releases less than
15 wt% of the total iron content as ferrous iron over the course of one hour
in simulated
gastric fluid at pH 1.6; the composition releases more than 10 wt%, 20 wt%, 30
wt% or 40
wt% of the total iron content over the course of one hour in simulated
intestinal fluid at pH
6.6; and/or the composition releases more than 80 wt% of the total iron
content over the
course of 2 hours in simulated intestinal fluid at pH 6.6.
In one embodiment, the composition further comprises a stabilizer, such as
ascorbic
acid, ascorbate, or a combination thereof.
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
3
In one embodiment, the iron : protein ratio is 1:20 to 1:5.
In one embodiment, the composition consists of particles having an average
particle
size of 2000 microns or less, 1000 microns or less, 600 microns or less, 500
microns or less,
or 300 microns or less, or 100 microns or less.
In one embodiment, the iron in the composition comprises at least 10%, 25%,
50%,
75%, 90%, 95%, 98% or 99% ferrous iron.
In one embodiment, the composition is more palatable than ferrous sulfate in
acidified water.
In one embodiment, the composition is stable with respect to ferrous iron
content
and microbiological burden, for at least 6 months when stored in a sealed
container at
accelerated storage conditions (40 C and 75% Relative Humidity).
In one embodiment, the composition is stable with respect to ferrous iron
content
when stored in a sealed container at ambient conditions for at least 24
months.
In one embodiment, the denatured protein comprises denatured whey protein,
denatured whey protein isolate, denatured beta lactoglobulin, or combinations
thereof.
Brief Description of the Figures
Figure 1 shows one equipment setup used in accordance with aspects of an
embodiment of the invention. First the protein solution is prepared as
described above,
pumped to a nozzle using either a syringe pump or air pressure system [2] with
introduction
of vibration (liquid or nozzle) [3] to form a droplet [4] which may have an
electrostatic
negative charge added [5] to aid dispersion and improve iron uptake into the
bead. Control
of droplet formation using e.g. flow-rate and vibrational frequency is
observed in the light of
a stroboscopic lamp [6]. The bead is formed in the curing solution with iron,
resulting in iron
uptake into the bead and contributing to the bead gelation [7]. Finally, the
gel bead is
collected, washed and dried to form the amorphous dry bead.
Figure 2 depicts an example of the comparative palatability data for the
ST1406
embodiment of the invention. The data show results from subjects (n=6)
randomly allocated
to aqueous dispersions of microbeads of the invention (ST1406) in apple juice
(100mL) in
comparison with equimolar doses of ferrous sulfate in acidified water and
apple juice
(100mL). The results show that the beads score highly on taste, after taste
and compliance
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
4
measures, all significantly greater (p<0.02) than ferrous sulfate in acidified
water. On
texture, there was no preference of either formulation on average, despite
differences in
formulation. Accordingly, beads prepared in accordance with the invention are
significantly
more palatable than FeSO4 in aqueous solution.
Figure 3 depicts an example of the comparative gastrointestinal tolerability
data for
the ST1406 embodiment of the invention. Three subjects from the taste test had
a history of
intolerance to ferrous iron preparations, even at low doses, and suffered
upper
gastrointesinal symptoms during the taste test. In a separate study beads
prepared in
accordance with the invention or FeSO4.7H20 in identical size 0 gelatin
capsules were taken
in the morning after fasting for 10 hours with baseline and 2 hour fasting
blood draws. After
2 hours, a modified Gastrointestinal Symptom Rating Scale (GSRS) was showed
show that
beads prepared in accordance with the invention are well tolerated.
Significantly higher
symptoms scores were observed for abdominal pain/cramps, nausea, flatulance
(all p=0.02)
and constipation (p=0.03).
Figure 4 depicts an example of the comparative iron ll profile in dissolution
from
5T1406 microbeads of the composition at pH 1.6 and pH 6.6 in the presence of
pepsin (pH
1.6 solution) and pancreatin (pH 6.6 solution). The detailed methodology is
described below.
This profile shows that the composition preferentially releases iron II in
experimental
conditions that mimic the small intestine- higher pH, digestive enzymes and
bile salts.
Figure 5 depicts an example of the iron ll and total iron (ferrous and ferric)
profile in
dissolution from the composition at pH 6.6 over 1 hour using the dissolution
methodology
described below in the presence of pancreatin and bile acids (pH 6.6
solution). Unlike
ferrous sulfate, which undergoes oxidation and precipitates as ferric
hydroxides, 5T1406
microbeads of the invention maintain release of iron into solution.
Figure 6 depicts an example of the comparative serum iron curves of 5T1406
microbeads of the invention and Fe504 at equimolar iron dose in fasting
subjects over 6
hours. The median Area Under the Curve 0-6hr (iirnol/L.hr) for serum iron with
microbeads
of the invention was 83.7 [IQR 97.5-72.5] compared to 42.1 [IQR 62.5-31.0]
p=0.025 with
Fe504. The relative bioavailability of microbeads of the invention (n=8) was
199% 36% of
Fe504 over 0-6 hours, p=0.025. Detailed description of the methodology is
described below.
The primary endpoint in this study is serum iron Trough to Peak Ratio (TPD)
over 0-6 hours
and the median TPD for microbeads of the invention was 20.1 iirnol/L [IQR:
16.1-21.7] while
the value for Fe504 was 9.7 iirnol/L [IQR: 7.4-13.6], p=0.017.
Figure 7 depicts results demonstrating that an intermediate hydrogel (wet)
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
formulation is less effective than dry ST1406 microbeads of the invention in
vivo (p<0.05)
using AUC measurements over 0-4 hours. Additionally, the hydrogels are more
prone to
oxidation and microbiological growth.
Figure 8 depicts relative bioavailability measurements of ST1406 microbeads of
the
invention in subjects with lower ferritin and higher ferritin (p<0.05 for
difference) using AUC
measurements over 0-4 hours. These data are consistent with the view that the
iron in
microbeads of the invention are actively absorbed and that as ferritin levels
decrease and
DMT-1 expression increases, there is greater bioavailability of iron in the
formulation.
Figure 9 is an SEM showing an image of a large bead at the intermediate
hydrogel
(wet) stage prepared for analysis by freeze drying to keep the surface
features intact. The
hydrogel interior network and morphologically distinct shell are evident at
this stage.
Figure 10 is an SEM showing an image of the bead at the intermediate hydrogel
(wet) stage prepared for analysis by freeze drying to keep the surface
features intact with a
close up of the skin formed on the microbead surface.
Figure 11 depicts (A) a low magnification SEM of an example of the microbead
of the
invention. (B) shows a zone close to the surface of the microbead. This is an
example where
folding of the skin has occurred during the drying process associated with the
microbead
volume reduction-shrinkage. (C) shows a further magnified zone close to the
surface of the
microbead with the fibrillary features associated with iron-mediated protein
aggregation.
Figure 12 depicts a low magnification SEM of an example of the microbead of
the
invention which have been mechanically fractured to provide a cross-sectional
view of the
matrix and skin. The scanning electron microscopy (SEM) images were recorded
on a Zeiss
Ultra Plus Field Emission SEM with a Gemini column (Zeiss). The dry sample
beads were
placed on a conducting carbon tape without any further preparation or sample
coating.
Accelerating voltages between 2-3kV was used to overcome the extensive
discharge effect.
Figure 13 depicts thermogravimetric analysis (TGA) of microbeads of the
invention.
Experiments were conducted on a Pyris 1 Thermogravimetric Analyser (Perkin
Elmer).
Weighed, powdered samples (10-15 mg) were analysed in open ceramic pans. All
samples
were measured under the following temperature program: isothermal at 30 C for
5min;
gradient from 30 C to 100 C; isothermal at 100 C for 20min; gradient from 100
C to 900 C at
C/min rate and under air purge. Sample water content is calculated from the
weight
difference at the end of the 100 C isotherm and the initial sample weight.
Figure 14a depicts an X-Ray Diffraction profile of calcium depleted denatured
whey
protein showing a largely amorphous profile. PXRD measurements were performed
on
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
6
samples placed on a low background silicon sample holder, using a Rigaku
MiniflexIldesktop
X-ray diffractometer (Rigaku, Tokyo, Japan). The PXRD patterns were recorded
from 5 to
80 on the 20 scale at a step of 0.05 /s. Xray tube composed of Cu anode
(XCuKa01.54 A)
was operated under a voltage of 30 kV and current of 15 mA. The broad baseline
peaks
however reflect low level order in the protein structure. Figure 14b depicts
an X-Ray
Diffraction profile of ferrous sulfate heptahydrate showing evidence of
crystallinity. Figure
14c depicts an X-Ray Diffraction profile of calcium depleted denatured whey
protein
physically mixed with ferrous sulfate heptahydrate showing evidence of
crystallinity. Figure
14d depicts an X-Ray Diffraction profile of ST1406 microbeads of the invention
with the
same iron/protein loading as the physical mixture (Figure 14b) and is largely
amorphous. .
There are no typical PXRD peaks present which are associated with crystalline
Iron(11) sulfate.
Figure 15 depicts results demonstrating that low concentrations of isolated
whey
protein are able to normalise reactive oxygen species (ROS) generation in an
adherent
monolayer of the colorectal epithelial adenocarcinoma cell line CACO2 in
response to iron.
The vertical axis denotes ROS with the normal control (NC) set at 100%. IP
refers to calcium
depleted whey protein.
Figure 16 shows the influence of electrostatic charge on iron loading in
ST1406
microbeads of the invention (p<0.01 for difference). The increased iron
loading while
retaining the gastro-protective effects of the microbeads is advantageous
because of cost,
efficiency and practicality of dosing.
Figure 17 shows the serum iron concentrations in fasting subjects (n=3) taking
Tardyferon at an elemental iron dose of 80 mg and subsequently crossed over to
ST1406
microbeads of the invention at an elemental iron dose of 25 mg
Detailed Description of the Invention
As used herein, the term "calcium-depleted" or "decalcified" or "at least
partially
subjected to divalent metal ion removal" shall refer to protein raw material
that has
undergone a divalent metal ion removal process, including but not limited to
the removal of
calcium. Preferably, a decalcified protein comprises less than 200mg calcium
per 100g
protein, less than 100 mg calcium per 100g protein, less than 50 mg calcium
per 100g
protein, or only trace amounts of calcium. Alternatively, a decalcified
protein may contain
(excluding iron) less than 1% divalent metal ions (w/w), less than 0.5%
divalent metal ions
(w/w), less than 0.1% divalent metal irons (w/w), or only trace amounts of
divalent metal
ions. There are standard methods of de-calcification of protein, apparent to
those skilled in
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
7
the art, including (a) acidification with dialysis and/or ultrafiltration
and/or diafiltration, and
or (b) using calcium chelating/sequestering agent(s) and/or (c) using cation
exchange
methods.
The term "protein-based carrier" as used in this specification should be taken
to
mean a substance at least partially derived from a protein-based source that
is combined
with a form of iron into a composition. The carrier may be used to render the
composition
suitable for its intended purpose. The purpose may be the effective delivery
of iron to a
mammalian subject. The protein carrier may provide advantages to the
composition.
Examples of such advantages include, but are not limited to, providing an
advantageous
modified iron-release profile to the composition, conferring additional anti-
oxidative effects
to the composition, reducing the level of gastrointestinal discomfort
resulting from
administration of the composition, and improving the level of iron uptake.
As used herein, the term "denatured protein" means a protein that is at least
partially denatured, i.e., at least 5% denatured.
As used herein "encapsulation" or "entrapped" means a process involving the
complete envelopment (entrapment) of pre-selected material(s) within a matrix
(usually
referred to as a bead or sphere or microbead) or a core-shell capsule (usually
referred to as
a capsule), to give particles ranging from a few hundred nanometers up to a
several
centimeters in size.
"Bound iron", as used herein, refers to iron that is not easily washed off and
"unbound iron" can be easily washed off. These terms are not intended to imply
covalent or
ionic bonding.
As used herein, the term "largely amorphous" means absence of evidence of
short
range order in the XRD associated with crystallinity. In other words, low
crystallinity.- See,
e.g., Figure 14.
As used herein, an "amorphous" substance includes a largely amorphous
substance.
A capsule is made up of a defined and distinctive core (consisting of the
encapsulated material) and shell part which are separated from each other. In
preferred
embodiments a microbead is a spherical structure which has (encapsulated)
material
distributed throughout the structure (i.e., a matrix). A microbead may have a
surface layer
("skin") having the same composition as the interior but with different
structure and
chemical properties to the interior. The skin thickness and structure may
influence
microbead properties and behaviour ¨ for example, swelling, pliability and
payload diffusion.
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
8
The iron-containing microbeads of the invention release only a limited amount
of
ferrous iron in simulated gastric solution at low pH and yet when delivered to
a mammal via
the oral route, results in greater bioavailability of the iron in vivo
compared to ferrous
sulfate (Fig. 6). Additionally, preferred embodiments of the invention reduce
adverse effects
(Fig. 3) and improve palatability (Fig. 2). This provides a way of maintaining
iron intake
without experiencing the adverse effects of medicinal products. It provides a
way of more
effectively maintaining iron intake using a supplement without other adverse
effects, such as
poor palatability associated with iron intake.
Thus, in one embodiment, the invention provides a preparation of microbeads
comprising discrete microbeads, in which the microbeads comprise iron and
denatured
protein. In one embodiment, iron is entrapped within a denatured protein
matrix core
having an aggregated denatured protein skin. Optionally, the skin may also
contain a gelling
agent, such as a complex carbohydrate, such as alginate, or a protein, such as
gelatin.
Additional iron loading can be achieved by applying a negative charge on the
surface
of the microdroplet prior to curing in an iron solution or by varying the
curing temperature
or level of protein denaturation or by incorporating substances such as
vitamin C (ascorbic
acid) known to chelate iron.
In one embodiment, the protein in the protein matrix has been subjected to a
divalent metal ion removal process that results in calcium depletion.
Suitably, the protein in the protein matrix comprises whey protein, another
milk
protein composition containing beta lactoglobulin, or pea protein. Preferably
the protein is
denatured whey protein or calcium depleted denatured whey protein.
In one embodiment, the microbeads comprise 0.1% to 10% iron (dry weight %).
Preferably, the microbeads comprise 0.2% to 7%, 0.5% to 7.0%, 1% to 6%, 1 % to
3%, 1% to
2%, 1% to 2.5%, or 2.5% to 10% iron. In another embodiment, the composition
contains an
iron content of up to 20% w/w, above 5% w/w, or between 5 and 10% w/w with
respect to
dry weight.
The percent iron can be estimated by instrumental or colorometric methods
following digestion of the microbeads. Total residual inorganic content which
reflects iron in
calcium depleted microbeads can be estimated by high temperature
thermogravimetric
analysis. Alternatively, the microbeads preferably have a ratio of
iron:protein ranging from
about 1:1000 to about 1:7 or 1:5, about 1:500 to about 1:7 or 1:5, about 1:500
to about
1:10, about 1:200 to about 1:10, about 1:100 to about 1:7 or 1:5, about 1:100
to about 1:10,
or about 1.2:100 to about 1:15, or other ranges of these ratios.
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
9
Typically, the iron in the microbeads contains ferrous (II) iron, which can be
derived,
for example, from ferrous sulfate, ferrous fumarate, ferrous gluconate,
ferrous bisglycinate,
ferrous taurate, ferrous citrate, ferrous ascorbate, ferrous chloride, ferrous
nitrate, ferrous
lactate, ferrous acetate, ferrous carbonate/siderite, ferrous oxides or iron
amino acid or iron
carbohydrate chelates or complexes. The composition of the invention may also
contain
ferric (III) iron or a mixture of iron ll and iron III. The iron content of
the composition
preferably contains at least 10, 25, 50, 75, 90, 95, 98 or 99 wt % ferrous
iron.
Preferably, the microbeads comprise acetate, citrate, phosphate, or ascorbate
counterions. In preferred embodiments, these ions improve stability by
reducing oxidation
of the ferrous iron and/or improves release or taste characteristics.
The invention also provides methods for increasing bioavailable iron in a
mammal,
such as treating or preventing iron deficiency, comprising the steps of
administering a
composition according to the invention (preferably microbeads) to the mammal.
A composition according to the invention can be administered by any delivery
vehicle known in the art. A preferred embodiment is an edible formulation,
such as a
powder (such as infant formula), prenatal vitamin formulation, multivitamin
formulation,
supplement, chewable supplement, gummy, food (such as chocolate or fat/oil),
beverage,
animal feed, tablet, capsule, or suspension. Lower-palatability embodiments
are preferably
in the form of capsules or coated tablets.
Compositions of the invention are preferably administered at a dosage
sufficient to
deliver an effective amount. One of ordinary skill in the art can determine
the needs of a
particular subject and take into account the bioavailability of the
composition of the
invention to determine an appropriate dosing regimen.
In one embodiment, beads are prepared by providing a carrier comprising
denatured protein and iron; forming the carrier into microdroplets; curing the
microdroplets
into beads; and drying the beads until the moisture content of the beads is
less than 10 %,
less than 7%, less than 5% or less than 3%, by weight.
In another embodiment beads are prepared by providing a carrier comprising
denatured protein and optionally iron; forming the carrier into microdroplets;
curing the
microdroplets into beads in a curing solution containing iron; and drying the
beads until the
moisture content of the beads is less than 10 %, less than 7%, less than 5% or
less than 3%,
by weight.
Preferably, the beads have a denatured aggregated protein skin.
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
If the microdroplets are cured by dropping them into a curing solution
containing
iron, in addition to iron, the curing solution may contain monovalent ions
such as sodium in
the range 100-1000 mM. Suitable sodium salts include sodium acetate, sodium
chloride and
sodium sulfate. The curing solution may also contain surfactants for example
tween. The pH
of the curing solution may be modified by introducing HCI or acetic acid or
ascorbic acid in
order to promote protein aggregation (curing of the microbead). Additional
iron uptake into
the microbead and improved shape can be achieved by applying a negative charge
on the
surface of the microdroplet prior to curing for example by using an
electrostatic charging
device.
Preferably the curing solution contains an organic acid such as acetic acid,
which
influences aggregation and curing (protein aggregation) through modification
of the pH and,
by transferring counter ions onto the protein side chains. The presence of the
acetate or
comparable counter ions may be detected in the resulting microbeads by
techniques such as
infra-red spectroscopy.
The cured beads can be washed to remove unbound or weakly bound iron prior to
drying. The washing may be performed using deionized water or by using aqueous
solutions
of acetate buffer, citrate or sodium ascorbate, for example. More washing will
generally
decrease the amount of iron in the composition.
Drying is preferably done in an oven at 50-100 C, preferably at about 80 C.
Alternatively, drying can be done at lower temperatures, such as room
temperature, under
vaccum. Preferably the drying is performed under an atmosphere of nitrogen or
argon.
In another embodiment, drying occurs between 15 C and 80 C, between 25 C
and
60 C, or at room temperature. In some embodiments, the step of drying may be
performed
under atmospheric pressure. In other aspects of some embodiments, the step of
drying may
be performed in at least a partial vacuum.
In aspects of some embodiments, the drying step results in the loss of between
40%
and 90% of total weight of the composition, or between 70-80% of total weight
of the
composition.
Drying can be performed in a rotating drum dryer under vacuum to reduce
exposure
to atmospheric oxygen while keeping particles in a constant motion to prevent
sticking of
the drying particles. Other techniques used for drying include using a
vibrational fluidized
bed dryer or rotary evaporator devices, which allow drying under controllable
atmospheric
conditions will keeping the particles in motion. Drying can also be performed
by supplying a
constant airflow or nitrogen flow over the microbeads.
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
11
In one embodiment, the invention relates to a preparation of microbeads in
which
the microbeads comprise a polymerized matrix formed from denatured calcium
depleted
protein having iron microencapsulated and/or entrapped within the matrix.
Typically, the microbeads have a generally spheroid shape. In some embodiments
the mean diameter is 2000 microns or less, 1000 microns or less, 600 microns
or less, 500
microns or less, or 300 microns or less. In some embodiments, the particle
size distribution
is narrow.
In some embodiments particles have a diameter of between 0.2 and 4000 microns.
The particles may be in the form of beads with a particle size between 0.2 and
4000 microns,
between 50 and 2000 microns, between 150 and 1000 microns, or between 300 and
600
microns in diameter. In some embodiments beads over a certain size may be
preferable
because they may display better flow characteristics, reducing the likelihood
of aggregation
during handling and the need for the use of an anti-caking agent or the like.
Alternatively,
the particles may be nanoparticles with a size below 0.2 microns.
The composition could comprise particles per se, or the composition could
comprise
the end result of such particles that have undergone one or more additional
processing
steps. This can be advantageous because in use, the protein may form a
protective coating
around the outside of the bead. This may result in a staged-release profile.
Microbead size can be varied within a certain range by regulating the
frequency of
vibration and/or the flow rate of the protein solution with higher frequencies
and lower jet
velocities enabling the generation of smaller whey protein droplets. The main
factor
governing iron microbead size in the embodiments of the invention exemplified
herein is the
nozzle diameter, either single or concentric, whereby the final dry microbead
diameter is
approximately 1.25X the size of the chosen nozzle, using this specific
technique.
In some embodiments, the microbeads of the invention are treated with acetate,
citrate, (such as tri-sodium citrate), or a phosphate (such as di-sodium
phosphate) or
ascorbate.
The microbeads of the invention can be made by extruding the calcium depleted
denatured whey protein suspension into a curing solution containing ferrous
iron. In one
embodiment a calcium depleted denatured whey protein solution/suspension is
extruded
using prilling through a nozzle to form a laminar jet in which break-up of the
extruded
laminar jet results in the formation of microdroplets. Preferably, these
droplets are rapidly
cured while maintaining their shape and avoiding high net positive surface
charge. The
microdroplets are preferably cured at elevated temperature, at low pH and high
ionic
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
12
strength produced by ferrous iron, sodium and sulfate ions. The microbeads of
the invention
are preferably dried at elevated temperature, preferably in a nitrogen
atmosphere. The
resulting microbeads preferably have <10 % moisture as indicated by
thermogravimetric
analysis.
In another embodiment, a ferrous iron containing solution is prepared and
separately a calcium depleted denatured whey protein suspension is prepared.
Preferably,
the solution and suspension are delivered to a vibrating nozzle, in which the
solution and
suspension are admixed at or just prior to the nozzle and simultaneously
extruding the
admixed solution and suspension through the vibrating nozzle to form a laminar
jet in which
break-up of the extruded laminar jet into microdroplets is induced by applying
a sinusoidal
frequency with defined amplitude to the nozzle. Preferably, the microdroplets
are cured
immediately in a curing solution to prevent oxidation and generate the
microbeads
comprising the ferrous iron entrapped within a crosslinked calcium depleted
denatured
whey protein matrix.
Preferably, the method includes an additional step of immersing the
microcapsules
in water or similar washing approach to reduce the unbound iron load. The
microbeads may
also be washed with a buffer comprising an acetate, citrate, phosphate or
ascorbate such
that the resultant microbeads are coated with an acetate, citrate, phosphate
or ascorbate.
One embodiment of the invention is a composition comprising iron and a carrier
comprising denatured protein. The iron in the composition preferably comprises
at least
10%, 25%, 50%, 75%, 90%, 95%, 98% or 99% ferrous iron. The denatured protein
preferably
comprises whey protein, whey protein isolate, beta lactoglobulin, or
combinations thereof.
Preferably, the denatured protein is at least 5% denatured. In one embodiment,
the
denatured protein contains at least 5% denatured beta lactoglobulin. The iron
: protein
ratio, by weight, is preferably about 1:1000 to about 1:10. Preferably the
microbeads of the
invention are dried at ambient pressure under nitrogen or argon. Preferably,
the
composition releases less than 50 wt% of the total iron content as ferrous
iron over the
course of one hour in simulated gastric fluid at pH 1.6; or less than 50 wt%
of the total iron
content as ferrous iron over the course of 30 minutes in simulated gastric
fluid at pH 1.6; or
less than 20 wt% of the total iron content as ferrous iron over the course of
30 min in
simulated gastric fluid at pH 1.6; or less than 15 wt% of the total iron
content as ferrous iron
over the course of one hour in simulated gastric fluid at pH 1.6. Preferably,
the composition
releases more than 10 wt%, 20 wt%, 30 wt% or 40 wt% of the total iron content
over the
course of one hour in a solution at pH 6.6 containing representative digestive
enzymes and
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
13
representative ionic strength and bile acid composition. The release rates are
based on the
testing methodology described herein.
Preferably, the composition, when administered orally to a human, has a
bioavailability at least 20%, 30%, 40% or 50% greater than that of an equal
dose of an orally
administered solution of ferrous sulfate in acidified water or a relative
bioavailability of at
least 120%, 130%, 140% or 150% that of an equimolar dose of an orally
administered
solution of ferrous sulfate in acidified water. Bioavailability is based on
the testing
methodology described herein for measuring serum iron AUC.
Preferably, the moisture content of the composition is less than 10 % by
weight, less
than 7% by weight, about 3-10%, about 3-7%, or about 5-7%.
Preferably, the carrier comprises a matrix of denatured aggregated protein. In
a
preferred embodiment, a matrix microbead structure forms upon the microdroplet
(such as
upon entering the low pH iron solution) that causes rapid aggregation and
curing on the
outer surface of the particle, producing a skin on the microbead whose
characteristics can
influence diffusion and degradation rates in the intestine. See, for example,
Figures 11 and
13.
In one embodiment, the composition comprises a stabilizer, such as Ascorbic
acid, or
Ascorbate (Sodium ascorbate, Calcium ascorbate, Fatty acid esters of ascorbic
acid),
Tocopherols (Alpha-tocopherol, Gamma-tocopherol, Delta-tocopherol), Propyl
gallate, Octyl
gallate, Dodecyl gallate, Erythorbic acid, Sodium erythorbate, Tertiary-butyl
hydroquinone,
Butylated hydroxyanisole (BHA), Butylated hydroxytoluene (BHT), or
combinations thereof.
In a preferred embodiment, the composition is more palatable than commercially
available iron formulations, such as ferrous sulfate in acidified water.
In a preferred embodiment, the composition is stable in that its dissolution
profile at
pH 1.6 and pH 6.6 changes less than 20%, less than 15%, less than 10%, less
than 5% or is
substantially unchanged with respect to iron ll release for at least 6 months,
preferably at
least 2 years, when stored in a sealed container at ambient conditions. In a
preferred
embodiment, the composition is stable with respect to microbiological burden
for at least 6
months, preferably at least 2 years, when stored in a sealed container at
ambient conditions.
Stability with respect to microbiological burden means the composition is
"free of
objectionable microorganisms", as that phrase is interpreted by FDA of 21 CFR
211.165.
Preferably, this includes a Total Viable Count with a Maximum Tolerable amount
of 103
cfu/1000mg, Total Yeast and Moulds Maximum Tolerable 102 cfu/1000mg, and an
absence
of E-Coli.
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
14
In preferred embodiments, the composition is in the form of microbeads for
oral
administration. Preferably, after oral administration the incidence of
constipation, as
assessed using the Bristol Stool Scale (described herein), is reduced by at
least 50% and/or
the incidence of nausea, as assessed using the modified Gastrointestinal
Symptom Rating
Score (described herein), is reduced by at least 50%. See Figure 3.
The term "calcium depleted" as applied to a composition should be understood
to
mean that the composition comprises less than 100 mg % (100 mg per 100 g
protein dry
wt%) of calcium. In some embodiments, the composition contains less than 0.1%
or only
trace amounts of calcium measured by standard methods.
Microbeads size can be varied within a certain range by regulating the
frequency of
vibration and /or the flow rate of the protein solution with higher
frequencies and lower jet
velocities enabling the generation of smaller whey protein droplets. The main
factor
governing iron microbead size in the embodiments of the invention exemplified
herein is the
nozzle diameter, either single or concentric, whereby the final microbead
diameter is
approximately 1.25X the size of the chosen nozzle, using this specific
technique.
Breakup of the jet can be monitored using a stroboscopic lamp (e.g. Figure 1)
placed
directly behind the protein droplet chain providing visualization of
individual protein-iron
drops during breakup. Droplet coalescence in the laminar jet stream will
result in loss of
monodispersity of iron microbeads. It is helpful for the formation of droplets
if the protein is
substantially negatively charged in solution. In the case of whey protein the
solution pH
should be above 5.2.
In certain embodiments, microbeads of the invention comprise (as a dry weight
%):
75-95% or 85-95% denatured, optionally calcium depleted, whey protein or whey
protein
isolate; and 0.1-10.0% iron.
The denatured whey protein may, for example, be a denatured whey protein
concentrate or denatured whey protein isolate. Methods for denaturing whey
protein will
be known to those skilled in the art, and include heat denaturation and
pressure-induced
denaturation. In one embodiment of the invention, the whey protein is heat
denatured at a
temperature of 70 C to 140 C, preferably about 80 C. The whey protein is
heated at a
temperature of greater than 70 C for more than 15 minutes. Usually, the whey
protein is
agitated during denaturation. Several methods for monitoring the
unfolding/denaturation
and formation of soluble oligomers will be known. These include dynamic light
scattering
and size exclusion techniques. It is useful to monitor the extent of thiol
exposure in whey
protein solutions using 5,5'-dithiobis-(2-nitrobenzoic acid) or DTNB which
produces coloured
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
adducts on reaction with exposed thiols. In a preferred embodiment, the extent
of
denaturation of the protein or beta lactoglobulin is greater than 80% or
greater than 90%,
which can be measured using DTNB.
In some embodiments, the protein employed in the process of the invention has
at
least 90%, 94% or 98% protein content (on a moisture, carbohydrate and fat
free basis).
Suitably, the concentration of the at least partially denatured protein
solution/suspension is from 4 to 30%, preferably from 7 to 30%, and ideally
from 9 to 16%
(w/v). Typically, the protein is whey protein, ideally, the suspension is
passed through a
series of filters having a gradually decreasing pore size.
Examples of iron salts include ferrous sulfate, ferrous fumarate, ferrous
gluconate,
ferrous bisglycinate, ferrous taurate, ferrous citrate, ferrous ascorbate,
ferrous chloride,
ferrous nitrate, ferrous lactate, ferrous acetate ferrous carbonate/siderite
ferrous oxides.
Ferric forms of these salts as well as ferric sodium diphosphate, ferric
ammonium citrate and
ferric chloride.
In other embodiments, the composition could contain or be prepared with ferric
and/or ferrous ion complexes or salts in anhydrous or hydrated states
containing for
example sulfate, phosphate, folate, acetate, propionate, maleate, benzoate,
salicylate,
fumarate, glutamate, aspartate, citrate, lactate, succinate, tartrate,
glycollate, hexanoate,
octanoate, decanoate, oleate, stearate, bisglycinate, fumarate, gluconate.
These iron
complexes and salts used could also be different iron oxides, oxide-hydroxides
or
hydroxides. The composition could be prepared with iron salts in mixed
oxidation states, and
their hydrates.
In one embodiment, the ferrous iron solution has a pH of less than 5 or less
than 4.5.
The curing solution is typically free of calcium ions. The curing solution has
a sodium
concentration of 0.1-1M or typically 0.2-0.5M. Suitably, the solution has an
organic acid
concentration of 0.1 to 0.6M, typically 0.15 to 0.25M, and ideally about 0.2M.
Typically, the
solution has a pH of 3 to 4.5, suitably less than 4. Generally, the solution
has a temperature
of 20-65 C, typically about 45 C. Typically, the acidic curing solution
comprises a surfactant
to prevent or inhibit agglomeration of the formed microbeads. Suitably, the
surfactant is a
polysorbate surfactant, ideally Tween 20.
Suitably, the formed microbeads are subject to an extended curing period in
the
curing solution, for a period of at least 15 minutes (after gelation), and
preferably for a
period of at least 20 minutes. In a preferred embodiment of the invention, the
formed
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
16
microbeads are cured for a period of time from 20 to 180, 20 to 120, or 20 to
60 minutes.
Ideally, the curing solution is agitated during the curing process.
The microbeads of the invention are typically capable of surviving intact
during
passage through the mammalian stomach and capable of releasing the ferrous
iron in the
gastrointestinal tract distally of the stomach, for example in the small
intestine. The term
"surviving intact in the stomach" means that the microbeads are resistant to
gastric and
peptic break-down in the mammalian stomach during gastrointestinal transit.
In certain embodiments, the microbeads of the invention are treated with
acetic
acid, citric acid, ascorbic acid solutions or their salts or phosphate
solutions, which further
improves ferrous stability and bioavailability in some embodiments. In some
embodiments,
the ascorbate or citrate or phosphate solution has concentration of 0.2 to
0.4M, 0.25 to
0.35M, or about 0.25M. Typically, the acid washing solution has a pH of 3-4,
or 4 to 4.5 to
5.5.
A preferred method of producing the microdroplets is a prilling by vibration
technique, in which the denatured calcium depleted protein and iron salt are
prepared
separately and not mixed until just prior to or during extrusion through a
nozzle and laminar
break-up of the extruded laminar jet is induced by applying a sinusoidal
frequency with
defined amplitude to the nozzle with defined aperture size. Examples of
vibrating nozzle
machines are the ENCAPSULATOR (BUCHI Labortechnik AG, Flawil, Switzerland), a
machine
produced by Nisco Engineering AG, or equivalent scale-up version such as those
produced by
BRACE GmbH and the like.
Typically, the nozzle has an aperture of between 60 and 2000 microns,
preferably
between 100 and 500 microns, suitably 140 and 300 microns, and ideally about
150 microns.
Suitably, the frequency of operation of the vibrating nozzle is from 100 to
20,000 Hz.
Optionally an electrostatic potential is added to the droplet, wherein the
electrostatic
potential between nozzle and curing solution is typically 0.15 to 0.3 V.
Suitably, the
amplitude is from 4.7kV to 7kV. Typically, the falling distance (from the
nozzle to the
acidification bath) is less than 50cm, preferably less than 40cm, suitably
between 20 and
40cm, preferably between 25 and 35cm, and ideally about 30cm. The flow rate of
suspension (passing through the nozzle) is typically from 3.0 to 20 ml/min; an
ideal flow rate
is dependent upon the nozzle size utilized within the process.
In one embodiment, the process involves a step of monitoring the size of the
initial
microbeads generated for suitability.
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
17
Suitable compositions include comestible products such as food products and
beverages, and food supplements in any form, for example unit dose products,
powders,
and the like. Typically food products include health drinks, yoghurts and
yoghurt drinks,
health bars, and the like. The composition may be a component of a formulation
which is
edible and orally active, e.g as an infant formula powder, prenatal vitamin,
multivitamin,
supplement, chewable supplement, gummy, food, beverage, animal feed, tablet,
capsule, or
suspension.
The preparation of microbeads of the invention may be provided in a dried
form, for
example a spray-dried, drum dried, dehydrated, or freeze dried form, or they
may be
provided as a suspension is a suitable solvent, for example water.
Denatured calcium depleted whey protein isolate (WPI) is preferable for
producing
microbeads of the invention. Whey protein concentrate (WPC) is also a possible
encapsulation material.
One aspect of this technology involves the use of denatured calcium depleted
whey
protein isolate /concentrate. In some embodiments, reducing the divalent metal
content of
protein raw material reduces spontaneous gelation of the protein solution
during
processing, enhances its iron binding characteristics and reduces calcium
release following
administration to mammals, therefore enhancing iron uptake. Calcium
competitively inhibits
iron uptake through DMT-1.
Dried calcium-depleted WPI is suitably dissolved in the optimum composition
for
iron microencapsulation. Calcium depleted whey protein isolate (WPI) can be
initially
denatured at appropriate environmental conditions (pH, salt, solid
concentration) to enable
the production of a soluble dispersion of protein aggregates suitable for
extrusion and
encapsulation in the presence of sodium acetate and ferrous sulfate. This
process can be
used to stabilize ferrous compounds in the matrix network of whey protein
micro-spheres.
This process occurs instantaneously when whey protein droplet comes into
optimal
conditions of electrolyte concentration, pH, agitation and temperature.
Ferrous and sulfate
ions in the curing solution can aid curing and allow iron uptake into the bead
through
diffusion and entrapment.
The preparation of calcium depleted whey protein (e.g., WPI) to form ferrous
encapsulation material typically involves:
1. Dispersion of calcium depleted WPI in water with concentrations in the
range of
4-30 % (w/w), between 7-30% (w/w), or between 9-16% (w/w). This may be
achieved, for
example, using high shear stirring in a blade mixer or Ultra-Turrax in the
range of 0.01-0.1%
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
18
(w/w), preferably in the range 0.04- 0.09% w/w), with a pH in the range of 5.0-
9.0,
preferably in the pH range 6.0 -7Ø A small amount of iron may be added at
this stage to
improve droplet viscosity/surface tension.
2. Application of filtration to remove any denatured material with filtration
pore size
of < 200 microns.
3. Application of heat treatment to induce protein denaturation (unfolding).
Protein
denaturation is suitably performed between 60-140 C, preferably between 70-
121 C at pH
in the range of 5.0- 8.5, preferably in the range of 6.0-8.2.
The calcium depleted denatured protein suspension can be extruded through a
concentric nozzle with a ferrous sulfate solution into a curing solution
containing acetic
acid/sodium acetate (0.1-5 M) buffering system with a pH 3-4.5, with
surfactant and
continuous agitation to reduce coalescence/aggregation at high flow rates. It
will be
understood that bringing the pH of the denatured protein solution close to its
isoelectric
point ("PI") will promote aggregation by reducing repulsive coulombic forces.
A number of techniques can be used to obtain the microbeads of the invention.
For
simplicity the methods can be categorized as mechanical, chemical or
physicochemical
processes and include techniques such as: chemical; in-situ polymerization and
interfacial
polymerization; physiochemical; complex coacervation and mechanical; spray-
drying and
extrusion based methods.
Mechanical techniques are based on the principle of generating droplets from a
polymer extruded through a nozzle (orifice) or from the breakup of a liquid
jet. They work
using mechanical means (i.e. cutting or vibration forces) to increase the
normal dripping
process at the orifice, or they break-up an extruded liquid stream produced by
the polymer
when it is passed through the nozzle. After production, the droplets are
immediately
solidified to spheres/capsules by either physical e.g. cooling or heating, or
chemical means
e.g. gelation. Several different mechanical based technqiues can be used to
encapsulate iron
and and other materials within whey protein matrices to produce particles with
the final
desired characteristics. Simple dripping is the oldest technology for the
production of
particles. The extrusion of a whey protein solution through an orifice
(nozzle) at low
velocities results in the extruded liquid sticking to the edge of the nozzle
until gravitational
force is high enough to overcome surface tension, resulting in the release of
a drop. A small
rise in the velocity increases the number of droplets formed, whilst further
escalation
amplifies droplet formation even further. After formation the droplets are
immediately
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
19
cured and the size of the resultant particles is mainly dependent on the
orifice diameter.
Produced beads usually have a size of more than 2 mm.
Electrostatic dripping is the acceleration of the normal droplet formation
process
using electrostatic forces to pull the droplets off the orifice at a
considerably faster rate
compared to the simple dripping process, whereby removal is based solely on
gravitational
force. An electrical potential is applied to the extruded whey protein
solution by passing it
through a charged nozzle, with the produced droplets subsequently falling into
the iron-
based curing solution, which has been earthed or holds an opposite charge.
This technique is
capable of producing smaller microbeads compared to normal dripping 50 microns
in
diameter), of uniform size and shape and is reproducible.
The coaxial air-flow technique like the electrostatic extrusion method, is
based on
the acceleration of the normal dripping process at an orifice, and uses a
stream of
compressed air to pull the whey protein droplets from the nozzle at a faster
rate compared
to the normal gravitational force. The coaxial concentric nozzle consists of
an inner orifice, in
which the whey protein solution is extruded and an outer orifice, through
which the
compressed air flows and strips the droplets formed at the tip of the internal
nozzle. The
process produces whey protein beads with diameters > 200 microns, of uniform
size and
shape.
The production of whey protein iron beads by vibrating nozzle technique is
based on
the principle of controlled breakup of the laminar jet by the application of a
controlled
vibrational frequency with defined amplitude to the extruded whey protein
liquid.
Formation of microbeads using this method typically involves use of an
encapsulator. See
Fig. 1. Suitably, the iron encapsulator consists of a single orifice for
transition of the
extruded calcium depleted denatured whey protein. When the calcium depleted
denatured
whey protein liquid is extruded through a nozzle, the exerted frequency causes
the
continuous liquid stream to break up freely into uniform droplets of equal
size which are
subsequently hardened by landing in a curing solution. The sinusoidal force
can be applied
by either vibrating the nozzle (vibrating nozzle technique), pulsating the
polymer in a
chamber before passing through the nozzle (vibrating chamber technique), or
periodic
changes of the nozzle/orifice diameter during extrusion. This technique can
produce whey
protein iron beads of less than 150 microns in size.
The vibrating technique can be used in combination with an electrostatic
charge to
produce droplets less than 100 microns in diameter. During droplet formation a
net negative
charge can be induced on the surface of the droplets using an electrostatic
voltage system.
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
The voltage system applies an electrostatic potential between the nozzle and
an electrode
placed beneath the nozzle. As the droplets fall through the electrode the
induced charge
causes them to repel one another and prevent coalescence, resulting in smaller
droplets
being formed compared to the standard procedure. Microbead size can be varied
within a
certain range by regulating the frequency of vibration and /or the flow rate
of the polymer
with higher frequencies and lower jet velocities enabling the generation of
smaller
microbeads of entrapped ferrous iron. Surprisingly, application of an
electrostatic potential
between the nozzle and an electrode placed beneath the nozzle also results in
significantly
higher iron content in the final microbeads of the invention (Figure 16).
Nonetheless, the
main factor governing microbead size is the nozzle diameter, whereby the final
microbead
diameter is approximately 1.00-1.25X the size of the chosen nozzle when dried.
A combination of co-axial and vibrating nozzle technqiues can be used with or
without the electrostatic charge to produce whey protein iron particles with a
size of less
than 50 microns. The whey protein solution is vibrated just before before
passing through
the co-axial nozzle and the resultant action of the two forces enables droples
of less than 50
microns to be formed. Due to the small size of the particles and the turbulent
conditions
(formed by the air flow) coalsecences of the droplets can form and increase
their size
substantially above 50 microns. The elctroctstaic charge system as already
mentioned causes
inhibits coalescence. The use of the electroctatic charge system enales higher
vibration
frequencies and air flows to be used for a given nozzle size, enabling smaller
whey protein
iron beads to be produced.
A further technique for making microbeads of the invention is the jet cutting
technique is based on the mechanical impact of a cutting wire on a liquid jet
of calcium
depleted denatured whey protein formed after extrusion through a nozzle. When
the whey
protein solution is forced through the nozzle at high velocity, a solid liquid
jet is formed
within a very short distance of the orifice. This jet can then be broken-up
into equal
cylindrical segments when passed through a cutting tool, which consists of
several wires
fixed onto a holder. Due to surface tension, these cylindrical segments form
spherical
droplets when passing through the air and are hardened after landing in a
curing solution.
The diameter of the resulting droplet is dependent on: (1) the number of
cutting wires; (2)
the number of rotations of the cutting tool; (3) the mass flow rate through
the nozzle and (4)
the mass flow depending both on the nozzle diameter and the velocity of the
fluid. This
method enables the production of small mono-dispersed homogenous shaped whey
protein
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
21
beads, > 200 microns to several millimeters in diameter, with a narrow
standard size
deviation using viscous fluids at high production rates.
A further technique is the spinning disk atomization is a technique which is
based
on the disintegrating of a feed liquid of calcium depleted denatured whey
protein which is
performed on disc(s) to produce droplets. When the whey protein solution is
dropped onto
the surface of a rotating disk it is centrifugally accelerated to a high
velocity which
distributes it as a thin film on the disc. Depending on the flow rate of the
feed, droplets are
then released due to the centrifugal forces at the tip (teeth) of the rotating
disk or from
ligamentry streams released from the edge of the disk. The droplets are then
gelled by
landing in a curing solution which is position to collect the projectile
droplets. The size of the
droplets produced is determined mainly by the rotation speed of the disk. This
technique
can produce produce calcium depleted, denatured whey protein microbeads 200
[im in
diameter with a narrow size distribution.
In the mechanical production procedures described above whey protein solutions
are extruded through a single orifice (nozzle) system (excluding co-axial
system) to produce
calcium depleted denatured whey protein droplets which are hardened in curing
solution
consisting of iron. Additionally the whey-iron particle can be produced using
a co-extrusion
technique which uses a double (concentric) nozzle system. The concentric
nozzle consists of
an internal nozzle, in which the iron solution is extruded through, and is
placed within an
external nozzle which the whey protein solution passes through. The liquids
meet at the tip
of each nozzle to form a co-extruded solution containing iron in the whey
protein solution.
This co-extruded liquid can then be produced into droplets using as
appropriate mechanical
procedure (excluding co-axial system) as described above, resulting in the
formation of a
microbead containing a defined core comprising of iron in a denatured whey
protein matrix.
The size of the core and membrane can be varied by the varying the size ration
of the
internal and external nozzle and using this system whey protein iron beads of
less than 200
microns can be formed.
Spray-drying is a unit operation in which a liquid polymer is firstly atomized
by a
compressed air stream and subsequently dried by a separate hot gas current in
a drying
chamber, allowing the formation of the particles. A 2-fluid nozzle is used in
which air passes
through an outside channel and atomizes the liquid stream passing through the
inner
channel. The liquid stream consists of a calcium depleted denatured whey
protein and iron
solution and is atomized into fine particles at the nozzle which are
immediately dried by
flash evaporation into whey protein beads entrapping the iron. The produced
particles are
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
22
collected using cyclone technology. This technique produces whey protein iron
particles of
between 10 ¨ 50 microns. The dried particles can be further treated in
additional curing
solutions if required.
Two other techniques, which are known to persons versed in the art are three
fluid
nozzle techniques used in conjunction with a spray dryer and microfluidic
devices.
One aspect of an embodiment of the invention comprises a composition
comprising
an amorphous preparation of iron salt associated with a protein-based carrier.
The iron in
the composition may comprise some ferric (Fe3+) iron. This may be advantageous
because
ferric iron, when delivered to the GI tract, may give rise to a reduced level
of gastrointestinal
discomfort compared to ferrous iron. Ferric iron is cabaple of undergoing
reduction in the
intestine to ferrous iron, the substrate for DMT1 activity. However, the
amorphous
preparation of iron salt associated with a protein-based carrier typically has
at least 50%
ferrous (Fe2+) iron which facilitates adequate bioavailability via absorption
mediated by
intestinal enterocyte DMT-1. Furthermore, the ferrous iron release from the
composition of
the invention at low pH and in the presence of the components of gastric fluid
such as
pepsin, is limited in order to protect the stomach and limit nausea, vomiting
and epigastric
pain.
In one aspect of an embodiment of the invention, the composition may be formed
by mixing an iron-containing composition with a protein-based composition, and
by drying
the resulting mixture. In another aspect, where the mixture comprises ferrous
iron, the
drying step may result in converting at least a portion of the ferrous iron in
the mixture to an
amorphous preparation of iron salt in the ferric form associated with a
protein-based carrier.
The drying process might make use of additional materials such as Silicon
Dioxide to prevent
"caking" of the composition during drying.
This dried composition may be advantageous over non-dry compositions
(including
gel preparations), which can be more variable and/or less stable on storage,
especially with
respect to oxidation, and inconsistent in their production, collectively
presenting challenges
for formulation, scale up and dose optimisation. Beads not subjected to
heating/drying
present additional formulation challenges due to their bulk. Furthermore,
undried
composition of iron present technical and cost challenges from a compatibility
perspective if
it is desired to incorporate iron into a multi-active supplement, for example
a multivitamin
and/or multi-mineral supplement.
In some embodiments, conversion of ferrous (2+) iron into ferric (3+) iron
during
production of the composition may be brought about during drying. In other
embodiments,
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
23
the conversion of ferrous (2+) iron into ferric (3+) iron can be limited
during drying by anti-
oxidative effects of the whey protein, drying in an inert (e.g. nitrogen)
atmosphere, and/or
by incorporation of a stabilizer with anti-oxidative effects. This can
include, but is not limited
to, the following in whole or in part: beta-carotene and carotenoids; vitamin
c; vitamin e;
zinc; selenium; copper; manganese; astaxanthin; black pepper extract; co-
enzyme 010;
lycopene; lysine based antioxidants, methylcobalamine; grape seed extract;
lutein; ginseng;
citrus bioflavonoids, orange peel extracts, green tea extract, ginko bilboa,
spru line, wheat
grass, barley grass, alfalfa, flax seed, banana leaf extract.
One embodiment of the invention is a method for making a composition
comprising
the steps of: preparing an iron-containing composition; preparing a protein-
based
composition (preferably denatured, calcium depleted whey protein/beta-
lactaglobulin);
mixing said ferrous iron containing composition with said protein-based
composition; and
converting at least a portion of the iron content of the mixture into an
amorphous
preparation of iron salt associated with a protein-based carrier. The iron-
containing
composition may comprise ferrous iron. At least a portion of the iron content
of the mixture
may be converted into a largely amorphous preparation of ferric iron
associated with a
protein-based carrier.
In another embodiment the method may be further specified such that: the
ferrous
iron-containing composition is a solution; the protein-based composition is a
suspension of
protein-based material; and the mixing comprises extruding the suspension
through a
vibrating nozzle such that the suspension is extruded in the form of
microdroplets, the
microdroplets being extruded into a bath comprising the solution such that
beads are
produced, the composition comprising said beads.
In some embodiments the conversion is achieved during drying of the
composition.
If the drying process is carried out in air or in the presence of oxygen, it
is believed that this
drying process has the effect of oxidising at least a portion of the iron
content such that it
changes from a predominantly ferrous (2+) state to an amorphous preparation of
iron salt
associated with a protein-based carrier where a proportion of the iron is in a
ferric (3+)
state.
In another embodiment, a divalent metal ion is substituted for iron in a
composition
described herein. Such metal ions include zinc, manganese, copper, chromium,
selenium,
molybdenum, combinations thereof, or combinations thereof with iron. In
certain
embodiments the resulting beads have improved palatability (e.g. Iron sulfate,
zinc sulfate).
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
24
Experimental
Generation of microbeads
(a) De-calcification of whey protein
WPI was treated with ion exchange resins to replace divalent (e.g. calcium)
cations
with monovalent cations.
(b1) Encapsulation of ferrous iron - Example 1 (ST1406)
Calcium-depleted WPI was used for ferrous encapsulation following particle
formation using the mechanical based techniques described above. The ferrous
iron
encapsulation system was prepared using the calcium-depleted WPI, which
contains (per
100 g) more than 1g elemental iron and up to 95 gram protein. Microbeads
composed of a
ferrous sulfate whey protein gel matrix were prepared using the extrusion jet-
breakup
technique. A stock solution of whey protein was prepared in phosphate buffer
(pH 7; 2M) in
a blade mixer or Ultra-Turrax in the presence of a surfactant in the range of
0.01-0.1% (w/w)
at pH range 6.0-7Ø The solution is filtered through a 150 micron filter.
Whey protein isolate
(WPI) was subsequently heat-denatured at appropriate environmental conditions
(pH 7.0,
>78 C; 4-11 % w/w protein content). Heat treatment was performed between 70-
140 C at
pH in the range of 5.0-8.5. Heat denaturation was performed under agitation
(150-200 rpm)
to enable the production of a soluble suspension of protein aggregates. Heat
denaturation
was performed for a between 30 and 90 minutes to allow denaturation and
exposure of
hydrophobic sites.
After Protein Activation (i.e. heat denaturation), the solution of aggregates
was
rapidly cooled to room temperature and then held overnight at 4 C with
constant agitation.
The resulting whey protein oligomer solution was extruded through a
multinozzle
plate into a curing solution maintained at 60-65 C, with a total molality of
5M), at pH 3.8,
containing ferrous sulfate 0.5M and Tween 20 at 0.035% (m/m). Spherical
microbeads were
obtained by the application of a vibrational frequency with defined amplitude
to the co-
extruded jet and collected in the curing solution placed 18 cm below the
nozzle and agitated
by a magnetic stirrer (length 4cm) in dish with diameter 35 cm. Polymer flow
rate and
vibrational frequency were empirically determined for the specific viscosity
and
concentration of calcium depleted denatured whey protein. Gel microbeads were
agitated
(50 rpm) for a minimum of 30 min. These microbeads were then recovered and
washed with
ultrapure, sterile water or first dispersed in tri-sodium citrate or sodium
ascorbate (up to
0.5M) for 15 minutes and subsequently washed with sterile water.
CA 02961430 2017-03-15
WO 2016/041995 PCT/EP2015/071141
(b2) Encapsulation of ferrous iron - Example 2
The microbeads of the invention can be manufactured by co-extruding the
calcium
depleted oligomeric whey protein solution through a concentric nozzle system
into a curing
solution containing sodium ions at 0.5 M with a pH adjusted to the range 3.2-
4.0 through the
addition of acetic acid. Spherical microbeads were obtained by the application
of a
vibrational frequency with defined amplitude to the co- extruded jet and
collected. The
appearance of a protein-iron gelation upon contact with acetate curing
solution, occurred at
a minimal calcium depleted denatured protein concentration of 2.5% (9% diluted
to 2.5%).
For the purpose of optimum ferrous encapsulation using a concentric nozzle
system, the
protein concentration must be greater than 5.5% (w/w) whey protein at pH
greater than 5.1.
Microbeads were recovered and dispersed in a second acidic solution (e.g. tri-
sodium citrate
0.25M) and subsequently washed with ultrapure water.
(b3) Scale up encapsulation of ferrous iron - Example 3
While producing iron containing whey protein hydrogel beads could produce
useful
beads at small scale, the conditions were not suitable for large scale
production. Some of
the issues include the high acetic acid content of the curing solution which
contributes to
spontaneous gelling in the extrusion nozzle, the droplet deformation of the
low density
protein solution when entering into the high density curing solution and the
coalescence of
the partially gelled protein beads on the surface of the curing solution. To
overcome these
difficulties the composition and properties of the curing solution as well as
the protein
solution was studied in detail and improved. Total elimination of the
buffering system
relying exclusively on iron(II) and sulfate electrolytes for gelling was found
to be unsuitable.
The most influential factors that governed the density, surface tension and
the
speed of gelation of the curing solutions and the results were interpreted
through statistical
analysis of the combinations of conditions described below.
Molality pH OAc- S042- Cl- W Isle
Fe2+ Ionic
(mol/kg (mol/kg) (mol/kg) (mol/ (mol/kg) (mol/kg) (mol/k
strength
solvent) kg) g) (0)
Buffer I. 3 3.5 0.152 0.500 0.000 0.000 0.152 0.500
2.17
Buffer I. 0.7 3.5 0.036 0.500 0.000 0.000 0.036
0.500 2.06
Buffer I. 3 4.0 0.324 0.500 0.000 0.000 0.324 0.500
2.34
Buffer I. 0.7 4.0 0.076 0.500 0.000 0.000 0.076
0.500 2.10
CA 02961430 2017-03-15
WO 2016/041995 PCT/EP2015/071141
26
Buffer I. 3 3.5 0.152 0.250 0.000 0.000 0.152 0.250
1.17
Buffer I. 0.7 3.5 0.036 0.250 0.000 0.000 0.036
0.250 1.06
Buffer I. 3 4.0 0.324 0.250 0.000 0.000 0.324 0.250
1.34
Buffer I. 0.7 4.0 0.076 0.250 0.000 0.000 0.076
0.250 1.10
Buffer II. 3 3.5 0.152 1.174 0.000 0.000 1.500 0.500
4.19
Buffer II. 0.7 3.5 0.036 0.657 0.000 0.000 0.350
0.500 2.53
Buffer II. 3 4.0 0.324 1.088 0.000 0.000 1.500 0.500
4.11
Buffer II. 0.7 4.0 0.076 0.637 0.000 0.000 0.350
0.500 2.51
Buffer II. 3 3.5 0.152 0.924 0.000 0.000 1.500 0.250
3.19
Buffer II. 0.7 3.5 0.036 0.407 0.000 0.000 0.350
0.250 1.53
Buffer II. 3 4.0 0.324 0.838 0.000 0.000 1.500 0.250
3.11
Buffer II. 0.7 4.0 0.076 0.387 0.000 0.000 0.350
0.250 1.51
Buffer III. 3 3.5 0.152 0.500 1.348 0.000 1.500
0.500 3.52
Buffer III. 0.7 3.5 0.036 0.500 0.314 0.000 0.350
0.500 2.37
Buffer III. 3 4.0 0.324 0.500 1.176 0.000 1.500
0.500 3.52
Buffer III. 0.7 4.0 0.076 0.500 0.274 0.000 0.350
0.500 2.37
Buffer III. 3 3.5 0.152 0.250 1.348 0.000 1.500
0.250 2.52
Buffer III. 0.7 3.5 0.036 0.250 0.314 0.000 0.350
0.250 1.37
Buffer III. 3 4.0 0.324 0.250 1.176 0.000 1.500
0.250 2.52
Buffer III. 0.7 4.0 0.076 0.250 0.274 0.000 0.350
0.250 1.37
The main factors that were found to influence the density were iron(II)
sulfate and
buffer concentration and the curing solution temperature. The surface tension
modified by
the surfactants (SDS, Tween 20, Tween 80) and the buffer concentration.
Different
surfactants have different effects on the curing solution. All of the selected
surfactants
seemed to have a great influence on the surface tension but the effect of
anionic surfactants
was found to be superior. Unexpectedly, the anionic surfactant significantly
decreased the
density of the curing solution. This is advantageous because it increases the
rate of
immersion of the solidifying microbead and promotes curing.
Non-ionic surfactant include polyoxyethylenes, poloxamer, poloxamine or
polysorbates, for example, but not exclusively Tween 20 or Tween 80.
Zwitterionic
surfactants, where the polar head group consists of a quaternary amine group
and a sulfonic
or carboxyl group include betaines or sulfobetaines and natural substances
such as
aminoacids and phospholipids (phosphatidylcholine, sphosphatidylethanolamine).
Anionic
surfactants can be sulfates, sulfonates, phosphate esters and carboxylates,
for example, but
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
27
not exclusively sodium lauryl sulfate (SDS).
Protein concentrations between 10.5-11.5 w/w% were prepared. Preferably the
protein solution had a concentration 10.5% otherwise spontaneous gelling
occurred
occasionally. The protein was denatured by either conductive or radiation
(microwave)
heating at a temperature between 60-100 C, ideally 80 C, for a time period of
30min-
120min, ideally 45min. The denatured protein solution was used immediately or
could be
aged at 4-8C for 1-24h, ideally 12h.
The molality of the curing solution was 0.35 mol/kg water while the low
settings of
the iron content was 0.125 mol/kg water. Tween 20 or SDS was used at its CMC
level. 0.125
mol/kg iron content generated bead droplets that sank rapidly and allowed a
large surface
area for faster gelling to occur.
In this approach to curing the extruded calcium depleted denatured whey
protein
solution, the sodium acetate-acetic acid buffer and a freshly prepared
iron(II) sulfate
heptahydrate solution were mixed in 1:1 solvent ratio. Tween 20 was also
added. The
molality of the curing solution acetate buffer ranged from 0.7 to 6.44 mol/kg
water before
mixing, giving a rise to 0.35 to 3.22 mol/kg water when calculated for the
curing solution.
The molality of the prepared iron(II) sulfate heptahydrate solution was in the
range of 0.25-
2.0 mol/kg water, giving a rise to 0.125-1.0 mol/kg water when calculated for
the curing
solution. The concentration of the surfactant was in the range of 1-5 times
its critical micelle
formation concentration (CMC) value. The pH of the curing solution, right
before the
beginning of the extrusion process was in the range of 3.2-4.2 and preferably
3.5-3.6. The
temperature of the curing solution during the extrusion process was in the
range of 20-65 C,
preferably 40 C.
Characterisation of microbeads
X-ray diffraction
PXRD measurements were performed on samples placed on a low background
silicon sample holder, using a Rigaku Miniflex ll desktop X-ray diffractometer
(Rigaku, Tokyo,
Japan). The PXRD patterns were recorded from 5 to 80 on the 20 scale at a
step of 0.05 /s.
Xray tube composed of Cu anode (XCuKa01.54 A) was operated under a voltage of
30 kV and
current of 15 mA.
Thermogravimetric Analysis
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
28
Thermogravimetric analysis (TGA) experiments were conducted on a Pyris 1
Thermogravimetric Analyser (Perkin Elmer). Weighed, powdered samples (10-15
mg) were
analysed in open ceramic pans. All samples were measured under the following
temperature
program: isothermal at 30 C for 5 min; gradient from 30 C to 100 C; isothermal
at 100 C for
20min; gradient from 100 C to 900 C at 10 C/min rate and under air purge.
Sample water
content is calculated from the weight difference at the end of the 100 C
isotherm and the
initial sample weight.
Scanning electron microscopy
The scanning electron microscopy (SEM) images were recorded on a Zeiss Ultra
Plus
Field Emission SEM with a Gemini column (Zeiss). The dry sample beads were
placed on a
conducting carbon tape without any further preparation or sample coating.
Accelerating
voltages between 2-3kV was used to overcome the extensive discharge effect.
In Vitro Dissolution
Measurement of Iron II
A solution of iron (II) sulfate in water (10 mM) was serially diluted using pH
1.8 KCI
buffer. Aliquots (100 ill) of the diluted solutions were added to a 96-well
plate containing
100 ill of 1,10-phenanthroline (5 mM). The plate was read at 490 nm on a
multiwall plate
reader in order to construct a calibration curve. Dissolution samples were
diluted ten-fold
typically at pH 1.6 into phenanthroline (5 mM) and the samples read rapidly
under N2
blanketing.
Measurement of Iron III
A 50 mg quantity of beads was transferred to a vial containing 10M HCI (10m1)
and
left overnight at room temperature. The resulting solution was shaken and then
a 100 ill
aliquot was transferred into 900 ill of 10M HCI. A 100 1 aliquot of the
diluted solution was
added to a 96-well plate containing 1M sodium thiocyanate (100 I). Absorbance
was
measured at 450 nm on a multiwell plate reader. The concentration of the iron
III was
estimated by reference to a series of iron III standard solutions.
Simulated Intestinal Dissolution Method
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
29
An accurately weighed sample (approximately 50 mg) of microbeads was
transferred
into a three necked vessel into which had been placed 15 ml pH 6.6 buffers
(containing 0.1
M sodium bicarbonate, 10 mg/ml bile acid extract, 1.85 mg/ml pancreatin,
adjust to pH 6.6
with 1M HCI) at 37 C. Generally, at 1, 15, 30, 45, 60 and occasionally at 90,
120 min time
points, samples were taken for iron (II) and iron (III) measurement. For iron
ll measurement,
100 ill of the dissolution supernatant was diluted into 900 ill pH1.8 buffer.
For iron III
measurement, a 100 ill aliquot of the dissolution supernatant was diluted to
900 ill in 10M
HCI and left overnight at room temperature. After the final time point, all
the buffer
solutions were taken out and 10 ml 10M HCI was added to the flask and left
overnight. The
beads were fully dissolved overnight and 100 ill solution was added to 900 ill
10M HCI for
total iron III level measurement.
Simulated Gastric Acid Dissolution Method
An accurately weighed sample (approximately 50 mg) of microbeads was
transferred
into 15 ml of pH 1.6 buffer containing NaCI (34.2 mM), sodium taurocholate (80
iiM), 0.1
mg/ml pepsin, and adjusted to pH 1.6 with 1M HCI at 37 C. Samples were
typically taken
for Iron (II) and Iron (III) measurement at 1, 15, 30, 45, 60, 90, 120 min.
For iron ll
measurement, 100 ill of the solution was removed and diluted into 900 ill pH
1.8 buffer. For
iron III measurement, 100 ill of the solution was diluted to 900 ill in 10M
HCI and left
overnight at room temperature. After the 2h time point, all the buffer
solutions were taken
out and 10 ml 10M HCI was added to the flask and left overnight. The
microbeads were fully
dissolved after overnight. A 100 ill aliquot was added to 900 ill 10M HCI for
total iron
measurement and indirect estimation of residual iron after 120 min
dissolution.
The iron ll and iron III dissolution methods were validated for accuracy and
precision.
Measurement of Iron II in the microbeads
A sample of microbeads was crushed in a mortar and pestle or milled in a ball
mill. A
1 g sample was transferred to a glass vial equipped with a magnetic stirrer,
to which was
added 10 mL dilute aqeuous HCI (0.1 M) which had been nitrogen sparged to
remove
oxygen. The suspension was heated to 500C and then subjected to
ultrasonication until the
crushed beads dissolved. A 0.1 mL aliquout was removed under nitrogen and
rapidly
transferred for measurement of iron ll using the phenanthroline method
described above.
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
Palatability data
Subjects (n=6) were randomly allocated to aqueous dispersions of microbeads of
the
invention (5T1406) in apple juice (100mL) in comparison with equimolar doses
of ferrous
sulfate in acidified water and apple juice (100mL) and asked to rate the
formulations for:
= overall taste on a Likert scale of 1-5 (Where 1 represents extremely
unpleasant
and 5 represents extremely pleasant);
= after-taste on a Likert scale of 1-5 (Where 1 represents extremely
unpleasant
after taste in your mouth and 5 represents extremely pleasant taste. 3
represents no noticeable taste);
= compliance and how satisfied they would be to take this supplement on a
daily
basis on a Likert scale of 1-5 (Where 1 represents extremely unhappy and 5
represents extremely happy. 3 represents indifferent);
= texture/mouth feel on a Likert scale of 1-5 (Where 1 represents extremely
unpleasant texture or feel in the mouth and 5 represents extremely pleasant
texture/mouth feel. 3 represents neither pleasant nor unpleasant texture or
mouth feel);
The results show that the beads score highly on taste, after taste and
compliance
measures, all significantly greater (p<0.02) than ferrous sulfate in acidified
water. On
texture, the two formulations are quite different, the invention being solid
beads and Fe504
being a solution. Despite this there was no preference of either formulation
on average.
Accordingly, beads prepared in accordance with the invention are significantly
more
palatable than Fe504 in aqueous solution. The results of this study are
presented in Figure 2.
In-vivo tolerability data
Three subjects from the taste test had a history of intolerance to ferrous
iron
preparations, even at low doses, and suffered upper gastrointesinal symptoms
during the
taste test. In a separate study using random, blinded, prospective allocation
to beads
prepared in accordance with the invention or Fe504.7H20 in identical size 0
gelatin capsules,
in-vivo gastrointesinal tolerability was assessed in a cross-over design. The
test articles were
taken in the morning after fasting for 10 hours with baseline and 2 hour
fasting blood draws.
After 2 hours fasting, food was taken as normal and over the following 24
hours, a modified
Gastrointestinal Symptom Rating Scale (GSRS) was completed. This rates the
following
symptoms as 0=none, 1=mild, 2=moderate, 3=severe:
= Abdominal pain/cramps
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
31
= Nausea/vomiting
= Abdominal bloating
= Borborygmus (abdominal rumbling)
= Flatulence/wind
In addition the products were taken on 3 consecutive days and the Bristol
Stool
Chart was used to assess constipation/diarrhoea. Positive score changes from
baseline
normality (=0) indicated constipation.
The results show that in the setting of established gastrointesinal
intolerance to
ferrous sulfate, beads prepared in accordance with the invention are well
tolerated.
Significantly higher symptoms scores were observed for abdominal pain/cramps,
nausea,
flatulence (all p=0.02) and constipation (p=0.03). Beads prepared in
accordance with the
invention are significantly better tolerated from a gastointestinal point of
view than Fe504
(see Figure 3).
In-vivo efficacy data
We evaluated the formulation in a randomised, double-blind, controlled with a
28
day cross-over to obtain a minimum of 6 paired evaluable healthy subjects with
serum
ferritin <100 ng/mL for comparison of the invention versus Fe504.
To be considered eligible for enrolment into the study, subjects were required
to:
1. Be able to give written informed consent;
2. Be between 18 and 40 years of age;
3. Be a non-pregnant female;
4. Be in generally good health as determined by the investigator.
Subjects were excluded from the study if they were:
1. Less than 18 and greater than 65 years of age;
2. Pregnant females, lactating or wish to become pregnant during the study.
[Included
female subjects were either of non-childbearing potential (i.e.,
physiologically
incapable of becoming pregnant, including any female who is post-menopausal or
any female who is surgically sterilized (via documented hysterectomy or
bilateral
tuba! ligation), OR were of childbearing potential, and not lactating and had
a
negative urine pregnancy test at the screening visit, visit 2 and upon
completion of
the study at visit 7. In addition, the subject if female and of childbearing
potential
also agreed to one of the following methods of contraception:
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
32
i. Complete abstinence from intercourse two weeks prior to administration
of
study drug, throughout the clinical trial, until the completion of follow-up
procedures or for two weeks following discontinuation of the study
medication in cases where subject discontinues the study prematurely.
(Subjects utilizing this method must agree to use an alternate method of
contraception if they should become sexually active and will be queried on
whether they have been abstinent in the preceding 2 weeks when they
present to the clinic for the Final Visit.) or,
ii. has a male sexual partner who is surgically sterilized prior to the
Screen Visit
and is the only male sexual partner for that subject or,
iii. sexual partner(s) is/are exclusively female or,
iv. Oral contraceptives (either combined or progestogen only) with double-
barrier method of contraception consisting of spermicide with either
condom or diaphragm. (Women of child-bearing potential using an oral
contraceptive in combination with a double-barrier method of
contraception are required to continue to use this form of contraception for
1 week following discontinuation of study medication).
v. Use of double-barrier contraception, specifically, a spermicide plus a
mechanical barrier (e.g. male condom, female diaphragm). The subject
must be using this method for at least 1 week following the end of the study
or,
vi. Use of any intrauterine device (IUD) with published data showing that the
highest expected failure rate is less than 1% per year. The subject must have
the device inserted at least 2 weeks prior to the first Screen Visit,
throughout the study, and 2 weeks following the end of the study.];
3. Hypersensitive to any of the components of the test product;
4. Suffered from a metabolic disorder;
5. Had any evidence of current infection (viral, bacterial, other);
6. Were taking any iron supplements;
7. Had a significant acute or chronic coexisting illness (cardiovascular,
gastrointestinal,
endocrinological, immunological, metabolic or any condition which
contraindicates,
in the investigators judgement, entry to the study);
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
33
8. Had a condition or taking a medication that the investigator believes
would interfere
with the objectives of the study, pose a safety risk or confound the
interpretation of
the study results;
9. Consumed more than the recommended alcohol guidelines i.e. >21 alcohol
units/week for males and >14 units/week for females;
10. Had a history of illicit drug use;
11. Were, in the opinion of the investigator, considered to be poor attendees
or unlikely
for any reason to be able to comply with the trial;
12. Subjects may not be receiving treatment involving experimental drugs. If
the subject
has been in a recent experimental trial, these must have been completed not
less
than 30 days prior to this study;
13. Had a malignant disease or any concomitant end-stage organ disease;
The study was conducted in accordance with the ICH Guidelines on Good Clinical
Practice, and the declaration of Helsinki.
From a screening cohort of up to 20 people, it was estimated that up to 12
healthy
subjects would be eligible for randomization and would result in 10 evaluable
subjects
subject to exclusion criteria. Based on previous clinical data using serum
iron measurements
in fasting subjects with normal haemoglobin and ferritin levels below 100
ng/mL over 6
hours, it was expected that the Trough To Peak Differential (TPD) of beads
prepared in
accordance with the invention would be at least 50% greater than Fe504 in
paired analyses.
The expected mean standard deviation of TPD for beads prepared in accordance
with the
invention will be 20.0 3.0 micromol/L. With 85% power and a two-sided alpha
of 0.05, we
required 6 subjects per group. Because this is a pilot study with a 10%
expected drop out, we
screened 20 subjects and aimed to include n=12 subjects per group in the cross-
over study.
A minimum of 6-paired evaluable subjects was required.
Subjects underwent an initial phone screen and were asked questions regarding
their eligibility for the study. Eligible subjects were scheduled for a
screening visit. Study
participation involved 3 study visits over a period of 4¨ 6 weeks.
At the first visit (Visit 1) the overall details of the study were explained
and informed
consent was obtained. Vitals, body weight and Body Mass Index (BMI) were
recorded and
medical history and general health was recorded. An Irritable Bowel
Questionnaire was
administered to determine whether subjects were at risk of any pre-existing
chronic
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
34
inflammatory bowel conditions. For women of childbearing age a urine sample
was collected
and pregnancy test performed.
During Visit 1, the subject's eligibility was determined by reviewing the
inclusion and
exclusion criteria (see above). A fasting venous blood sample (8m1) was
collected and a full
blood count was performed to evaluate potential for intercurrent infection,
along with
serum iron, transferrin saturation and ferritin. Subjects were between 18 and
65 years of
age.
The visit windows are set as outlined in the table and text below:
Day Screening Day 1 Day 28
Visit 1 2 3
Informed Consent X
Inclusion/ Exclusion X
Vitals X
Demographic Data X
Fasting Blood Sample (8m1) X
Urine Pregnancy Test (if
X
applicable)
Randomization X
Study Product Administered X X
Blood Sampling (20mIs) X X
Adverse Events recorded X X
Concomitant Medications
X X
Record
In the analyses, comparisons between groups were conducted using paired sample
t-tests for continuous variables and Wilcoxon's Rank Order tests for non-
normal
distributions. Shapiro-Wilks tests for normality were used to confirm
assumptions that
primary and secondary endpoints in the study population come from a normal
distribution.
If assumptions of normality were not possible, log-transformation was used or
Wilcoxon's
Rank Order tests were applied.
All analyses were two-sided, and significance set at a = 0.05. Chi-squared
analyses,
was used to compare categorical variables. Data were presented as the mean
value the
standard error of the mean for continuous variables unless otherwise stated
while
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
frequencies and percentages were used for categorical variables. All analyses
were carried
out using SPSS V.11 statistical software (Statistical Package for the Social
Sciences: SPSS Inc,
Chicago, Illinois, 2001).
Study Visits
Screening Visit (Up to day -28/ Visit 1)
From the screening visit, two males and eight females were selected to
continue in
the study, based on their serum iron and ferritin levels. A fasting blood
sample (8mIs) was
collected at the screening visit, and a full blood count (FBC), serum iron,
unbound iron
binding capacity, derived total iron binding capacity and transferrin
saturation were
calculated. Ferritin and haemoglobin were also assessed. A white cell count
was used to
confirm absence of intercurrent infection.
Visit 2 (Baseline/Day 0)
Subjects returned to the study site (within two weeks of Visit 1) for the
first
intervention day (Visit 2), after fasting since 10pm the previous night.
Subjects were pre-
randomised into one of the two treatment groups with a washout period of four
weeks
between treatment phases:
= Group 1: beads prepared in accordance with the invention, followed by
Fe504
= Group 2: Fe504, followed by beads prepared in accordance with the
invention
A blood sample was collected immediately after drinking the supplement and at
2
hours, 4 hours and 6 hours after dosing. A full blood count (FBC) was carried
out as well as
serum iron, unbound iron binding capacity, derived total iron binding capacity
and
transferrin saturation. Ferritin and haemoglobin were also assessed. A white
cell count was
again used to confirm absence of intercurrent infection. At follow up
timepoints, 4 mLs
blood was drawn and serum iron, unbound iron binding capacity, derived total
iron binding
capacity and transferrin saturation were reassessed. A total of 20mIs of blood
was collected
throughout the study day.
Water was consumed ad libitum, and after the 4-hour blood collection, a light
snack
with low iron content was given to the subjects. Subjects were observed during
the duration
of the study, were not allowed to leave the test centre and were not permitted
to have any
other foods or drinks because of the risk of interference with iron analysis.
Subjects were
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
36
queried about any changes in their health status. Any adverse events or
serious adverse
events were recorded.
Visit 3 (Baseline/Day 28)
Subjects returned to the study site after a four-week washout for the cross-
over and
during this period they were instructed to follow their standard diet and
exercise routine
and not consume medications, especially iron supplements, that could interfere
with the
assessment of the study product.
During the follow up visit (day 28), a full blood count (FBC) was carried out
as well as
serum iron, unbound iron binding capacity, derived total iron binding capacity
and
transferrin saturation was carried out at baseline, following an 10 hour
overnight fast from
food and tea/coffee. Ferritin and haemoglobin were also assessed. Once again,
a white cell
count was used to confirm absence of intercurrent infection.
Subjects were given a single dose of the alternative test supplement. At
follow up
timepoints, 4 mLs blood was drawn and serum iron, unbound iron binding
capacity, derived
total iron binding capacity and transferrin saturation were reassessed..
All samples were shipped directly to Biomnis for analysis. A total of 48mIs of
blood
was collected from each subject throughout the study.
Subjects were withdrawn from the study if the subject:
= Elects independently to withdraw from the study;
= If he/she develops any condition which contravenes the original criteria;
= Is considered at any point to be unsuitable to continue the study, at the
discretion of the investigator.
Results
The primary endpoint in this study is serum iron Trough to Peak Differential
(TPD)
over 0-6 hours and shows superiority of 5T1406 beads prepared in accordance
with the
invention over Fe504. This is presented as mean ( SEM) increase in serum iron
from
baseline in Figure 6 The median TPD for the beads was 20.1 iimol/L [IQR: 16.1-
21.7] while
the value for Fe504 was 9.7 iimol/L [IQR: 7.4-13.6], p=0.017. Figure 6 also
presents the
relative time course of mean ( SEM) serum iron profile over the study period
for both test
articles. Compared to Fe504, there were significant differences between serum
iron levels
at timepoints 2 hours and 4 hours in the analysis of the beads (both p<0.05).
The combined
values within each group for the primary and secondary efficacy measures at
time 1 and
time 2 were found not to significantly deviate from normality (Shapiro-Wilks p
values all >
0.05).
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
37
For the secondary endpoints, the median AUC 0-6hr (iirnol/L.hr) for serum iron
with
beads was 83.7 [IQR 97.5-72.5] compared to 42.1 [IQR 62.5-31.0] p=0.025. The
relative
bioavailability of beads (n=8) was 199% 36% of FeSO4 over 0-6 hours,
p=0.025. Similar
results were found with transferrin saturation (TSAT) % and 5T1406 microbeads
showed
significantly greater 2 hour TSAT % with beads compared with Fe504 in paired
analysis. The
data demonstrate that beads outperform Fe504 on all serum iron measures of
efficacy.
Consistent with preliminary clinical testing, there were no reports of adverse
events with the
beads.
Example 3: Determination of optimum means of mixing
In one embodiment of the invention, the maximum premix load of iron for mixing
with 9% whey protein isolate was 10-15 mM ferrous sulfate. In some
embodiments, pre-
processing of the protein-based material, solution pH and the form of iron
used had an
effect on the product. For example, in some embodiments, adequate hydration of
the
protein-based material was required and ferrous sulfate heptahydrate was found
to be
preferable to dried ferrous sulfate because of the better water solubility and
purity.
Example 4: Preparation of the protein-based solution
In one embodiment of the invention, whey protein isolate (WPI) was dispersed
in
250 mL sterile water 10.5% w/v and left to hydrate for 2-16 hours at 4 C under
slight
agitation (180 rpm). The pH of the dispersion was adjusted to 7 using HCI. The
pH adjusted
dispersion was optionally filtered through successive filters and then
optionally finally
through Durapore60.45 iirn HVLP. The protein dispersion was then heated to 80
(75-90) C
for 45 -60 min under agitation (95 rpm). The dispersion was then cooled on ice
and stored at
4 C for 16 h.
Example 5: Preparation of the curing solution
In some embodiments of the invention, the pH of the iron salt-containing
curing
solution (containing monovalent or divalent metal ions in the range 0.1 to 0.5
M) was
adjusted to between pH 4.0 and 6.5. Ideally a pH of between 4.5 and 5.5 is
used for the
curing solution. Ferrous sulfate (0.1 to 1.0M) was added to the curing
solution and pH
further adjusted. The solution was then heated to 45 C. Optionally a low
concentration
surfactant was added. The solution was then maintained at 45 C.
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
38
Example 6: Encapsulator set up
The following description is made with reference to Figure 1. The falling
distance for
the curing solution was set to approximately 30 cm. The curing solution was
stirred at 100
RPM. The 200 micron nozzle was attached to the vibrating nozzle apparatus. The
following
encapsulator set up applies to the Buchi/Inotech encapsulator, by way of
example, but the
person having skill in the art would appreciate how to implement analogous
setups using
other equipment. Set the vibrating nozzle to 1500 Hz, turn on the stroboscopic
lamp, set the
flow to 2-4 mL/min and adjust until a droplet chain is obtained, turn on the
electrostatic
dispersion unit with electrostatic tension of greater than 1.0 kV, an
amplitude of 7.0kV (4.7
to 7kV), adjust the vibration (1000 to 2000) Hz to optimise bead formation,
leave beads in
the curing solution for 30 minutes. Bead particle size can be modulated by
varying
processing conditions such as the nozzle size, flow rate, vibration frequency.
Example 7: Gel Bead Production
The pH of the curing solution is monitored and maintained at pH 3.2 to 4Ø
After 30
minutes of curing, the beads are filtered and washed with water at room
temperature. The
beads are sampled (known weight) and the iron content of beads is confirmed
per w/w gel
bead for the batch using sodium thiocyanate method following dissolution in
10M HCI. A
sample of the gel beads is used immediately for evaluation of release of
ferrous iron or
stored in an airtight container with N2 atmosphere to minimise oxidation of
ferrous to ferric
iron. Optionally, the beads can be prepared under N2 atmosphere or in the
presence of anti-
oxidants to preserve the iron form in a reduced state if ferrous starting
material is used.
Example 8: Production of dry, amorphous preparations of iron associated with
protein
The gel beads are dried at 25 C for 16 hours or at up to 80 C for 2-16 hours
to form
dry, amorphous preparations of iron associated with protein beads.
Thermogravimetric
analysis is used to determine the water content of the amorphous iron. The
beads are
sampled (known weight) and iron content of beads confirmed per w/w dry bead
for the
batch using sodium thiocyanate method following dissolution in 10M HCI. The
dry,
amorphous iron-protein beads are sealed in an airtight container.
Example 9: Bead analysis
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
39
A standard sodium thiocyanate method was used to determine the total iron
content of the protein beads and expressed as %w/w beads. Total iron was
determined by
treating approximately 100mg beads with 100m1 of 10M HCI at 60 C for two hours
to fully
dissolve the beads. Then solution was diluted to 10 times in 10M HCI. 100 ill
of diluted
solution was reacted with 100 ill 1M sodium thiocyanate. The concentration of
the iron III
ions was determined by measuring absorbance of the complex at 495nm and
comparing to
the calibration curve. In addition to light microscopy, further image analysis
was performed
using a Leica TCS SP5 confocal scanning laser microscope (CSLM) for the
purpose of micro-
capsule morphology assessment. The mean size distribution and D (v, 0.9) (size
at which the
cumulative volume reaches 90% of the total volume) was evaluated using fifty
beads per
batch, which were analysed using a bright-field light microscope at a
magnification
maximum x40.
The dissolution profile of the beads was studied by incubating the beads in pH
1.6,
pH 6.6, and pH 8.4 buffers at 37 C degrees. The iron !land iron III levels
were measured at
0, 15, 30, 45, 60, 90, 120 minute time points. Iron 11 level was measured by
taking 100 ill of
the solution at each time points into 900 ill water, Iron Ilion was determined
by the
standard complexometric titration with 5mM 1,10 phenanthroline by measuring
absorbance
of the complex at 450nm and comparing to the standard curve. Iron 11
measurement was
carried out with appropriate suppression of artifactual oxidation to iron III
by performing
analysis under a nitrogen atmosphere. For iron III measurement, 100 ill of the
solution was
diluted to 900 ill 10 M HCI and left overnight at room temperature to oxide
fully. Iron III
content was determined using the standard sodium thiocyanate method described
above.
An upper limit of approximately 9% betalactoglobulin - BLG - (11% denatured
WPI
equivalent to 9% BLG) was used to avoid spontaneous gellification of the
BLG/WPI. Bead
production was performed using a curing solution comprising up to 250-1000mM
sodium
acetate along with up to 250-1000mM ferrous sulfate, with curing for 30
minutes. The gel
beads produced contained between 0.5 and 2% w/w iron and when dried using
conditions
ranging from 15 C for 16 hours to 70 C for 2 hours, the compositions had
between 2.5 %
w/w iron and 10% w/w iron respectively.
The gel beads made were up to 8000 microns in diameter and the resulting dry,
amorphous iron-protein beads had a diameter ranging from one third to one half
the
diameter of the gel beads. Three batches of beads made using 10.5% WPI
solution cured
with 250-1000mM sodium acetate along with up to 250-1000mM ferrous sulfate,
with
curing for 30 minutes were tested using different processing conditions
allowing formation
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
of a predominantly Fe3+ releasing bead or preserving the iron in the
predominantly Fe2+
state. These had average particle diameters of between 1.84 mm 0.12 mm and
2.10 mm
0.16 mm (average 1840 and 2100 micron respectively). Further batches of
micronized beads
(100-300 micron) were made using microencapsulation technology and the results
show
improved absorption of iron with a compromise on processing characteristics
such as flow
and aggregation at low particle sizes, which can be improved by addition of
silicon dioxide.
The dry, amorphous iron-protein beads have better flow characteristics than
gel beads,
which makes them more amenable to formulation. Furthermore, the dry, amorphous
iron-
protein beads can be more easily formulated in regular capsules unlike gel
beads. They can
be co-formulated with vitamins and minerals without disruption of the bead
structure or
dissolution of the water-soluble vitamins which can promote instability of the
vitamins and
also loss of gel structure.
The dry, amorphous iron-protein microbeads produced are durable and stable. It
has
been shown that dry, amorphous iron-protein microbbeads left in ambient and
accelerated
stability storage conditions for several months show solid-state
characterisation similar to
the original beads and also perform as well as freshly made samples in terms
of iron ll
release at pH 6.6.
When the dry, amorphous iron-protein beads are dissolved in water, they absorb
water within 15 minutes and a gel diffusion layer is formed surrounding the
dry bead, which
is responsible for the modified iron release profile.
Ground, freeze dried beads are much less effective in-vivo. Also, in-vitro
dissolution
of ground, poorly formed dry gel beads rapidly results in a more immediate
release profile.
Example 10: In-vitro dissolution of compositions
Known quantities of the beads containing approximately 2-4mg of elemental iron
were dissolved into 10 mL of buffered solution to ensure sink conditions with
respect to the
ferrous sulfate iron at pH 1.6 and maintained at 37 C in a temperature
controlled bath. The
solutions were covered to prevent evaporation. At baseline and 15, 30, 45, 60,
90, 120
minute time points, 2 x 100 ii.L aliquots of the solution were removed for
analysis of iron.
One of the aliquots was immediately diluted into 900 ill water to measure the
iron ll content
in the solution by the standard complexometric titration with 1,10
phenanthroline. The
other aliquot was preserved for iron III measurement, where 100 ill of the
solution was
diluted to 900 ill 10 M HCI and left overnight at room temperature to oxide
fully. Iron III
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
41
content was determined using the standard laboratory isothiocyanate method.
Experiments
were conducted in triplicate.
Example 11: Clinical evaluation of dry, amorphous iron-protein beads
Inclusion Criteria
Participants were considered eligible for enrollment into the study, if they
were:
1. able to give written informed consent;
2. between 18 and 52 years of age;
3. non-pregnant, if female; and
4. in generally good health.
Exclusion criteria
Subjects were excluded from the study if they met any of the following
criteria:
1. were less than 18 and greater than 65 years of age;
2. were pregnant, lactating or wished to become pregnant during the study;
3. were menstruating within 3 days of the study visit;
4. were hypersensitive to any of the components of the test product;
5. suffered from a metabolic disorder;
6. had any evidence of current infection (viral, bacterial, other) as
indicated by
a raised white cell count;
7. were taking any iron supplements or preparations;
8. had a significant acute or chronic coexisting illness (cardiovascular,
gastrointestinal, endocrinological, immunological, metabolic or any condition
which
contraindicated, in the investigators judgement, entry to the study);
9. had a condition or was taking a medication that the investigator
believed
would interfere with the objectives of the study, pose a safety risk or
confound the
interpretation of the study results;
10. consumed more than the recommended alcohol guidelines i.e. >21 alcohol
units/week for males and >14 units/week for females;
11. had a history of illicit drug use;
12. were, in the opinion of the investigator, considered to be poor
attendees or
unlikely for any reason to be able to comply with the trial;
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
42
13. subjects were not to be receiving treatment involving experimental
drugs. If
the subject had been in a recent experimental trial, these must have been
completed not
less than 30 days prior to this study;
14. had a malignant disease or any concomitant end-stage organ disease.
Study visits
The visit windows were set as outlined in the Table 1 and the text below.
Table 1
Screening Study
Day
Visit Visit
Informed Consent X
Inclusion/ Exclusion X
Vitals X
Demographic Data X
Fasting Blood Sample (8m1) X
Urine Pregnancy Test (if applicable) X
Randomization X
Study Product Administered X
Fasting Blood Sampling (20m1s) X
Taste questionnaire X
Adverse Events recorded X
Concomitant Medications Record X
Screening Visit (Visit 1)
Subjects were recruited from a volunteer database. An initial phone screen was
performed, where subjects were asked questions regarding their eligibility and
general
health. At the baseline visit fasting venous blood sample (8m1) was collected
and a full blood
count was performed, along with serum iron and ferritin. Eight females were
selected to
continue in the study, based on their serum iron and ferritin levels and
subjects were
requested to return to the study site within the next two weeks for the study
visit. During
this period they were instructed to follow their standard diet and exercise
routine and not
consume medications that could interfere with the assessment of the study
product.
Study Visits
Subjects attended this visit fasting from food and tea/coffee since 10pm the
previous night. The study was to investigate the effects of oral
supplementation of iron with
the dry, amorphous iron-protein beads in comparison with wet gel-iron-protein
beads where
the iron is dissolved in water and also a commercially available iron
supplement, comprising
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
43
ferrous sulfate in acidified water, Spatone . In the successive studies,
subjects were
randomly allocated into one of the two treatment groups and were given a
single dose of a
supplement, mixed with 100mIs of apple juice. A blood sample was collected
immediately
before drinking the supplement and at 2 hours and 4 hours after dosing. A
total of 24mIs of
blood was collected throughout the day. Water was consumed ad libitum, and
after the 4-
hour blood collection, a light snack was given to the subjects. Subjects were
asked to
complete a questionnaire relating to the taste, tolerability and palatability
of the
supplement. Subjects were queried about any changes in their health status.
Any adverse
events or serious adverse events were recorded. Subjects returned to the study
site after a
wash-out period of at least two weeks. During this period they were instructed
to follow
their standard diet and exercise routine and not consume medications that
could interfere
with the assessment of the study product. Subjects returned to the study site
after a
minimum wash-out of two weeks, and following an 10 hour overnight fast from
food and
tea/coffee. Subjects were crossed-over to the second phase of the study and
were given a
single dose of the alternative supplement at the same dosage as the supplement
delivered
in the first phase of the study, mixed with 100mIs of apple juice. Study visit
procedures were
as described above.
Removal of subjects from the study and concomitant medication
Subjects were withdrawn from the study if the subject elected independently to
withdraw from the study; if he/she developed any condition, which contravened
the original
criteria; or was considered at any point to be unsuitable to continue the
study, at the
discretion of the investigator. No withdrawals occurred. Subjects were
questioned about
their medication history. The details of any medication taken were recorded in
the
participant case notes and case report form.
Biological Sample Collection and Analysis
A fasting blood sample (8mIs) was collected at the screening visit, and a full
blood
count (FBC), Serum iron and ferritin was assessed. During the intervention
days, blood was
also collected at baseline (8mIs), 2 hours (4mIs) and 4 hours (4mIs). Full
Blood Count, serum
iron, ferritin and iron binding capacity was measured at baseline, serum iron
was assessed at
2, and 4 hours and ferritin and iron binding capacity was also measured. All
samples were
shipped to an approved contract laboratory for analysis. A total of 24mIs of
blood was
collected throughout the study.
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
44
Treatments Administered
We compared a wet gel iron-protein bead composition with ST1406 nnicrobeads of
the invention comprising iron predominantly in the ferrous (Fe2+) state. Also,
we analysed
the comparative performance of the ST1406 nnicrobeads of the invention versus
a solution
of ferrous sulfate in acidified water.
Storage of study product
Study product was stored in a secure area with restricted access and was
dispensed
only to study subjects who had provided written consent. The investigative
product was
stored at room temperature away from moisture, direct heat and sunlight.
Treatment doses
were adjusted for any product remaining in the administration vehicle and, a
priori, subjects
were deemed ineligible if the dose administered was less than 30% of the
prepared dose.
None of the subjects were excluded on this basis. The in-vivo results are
presented as area
under the curve over the study period calculated using the trapezoidal method
and adjusted
for the final dose administered.
Statistical Analysis
For continuous variables, summary statistics were presented as the mean (SD)
or
median and 25th to 75th percentiles (interquartile ranges). Comparisons
between groups
were made using paired and independent-t, Mann-Whitney, or Chi-square tests
where
appropriate.
Results
Powder X-Ray analysis was performed using a Miniflex II Rigaku
diffractonnether with
Ni-filtered Cu Ka radiation (X=1.54A). The tube voltage and tube current used
were 30 kV
and 15 nnA respectively. Each sample was scanned over 2 theta range 5-80 with
a step size
of 0.05 Vs. As can be seen from Figures 16-19, the XRD traces for the physical
combination
of whey protein and Fe504.7H20 in proportions similar to the composition of
5T1406 (dry
Fe2+ releasing beads) show the presence of peaks at scattering angles 2 theta
(degrees) =
12.9, 16.3, 19.9, 22.5, 26.3 and 30.1 which are absent from 5T1406, confirming
that the
ferrous sulfate composition is largely in an amorphous physical state.
In some embodiments, isolated whey proteins combined with ferrous iron at low
concentrations can increase CACO2 cell formation of reactive oxygen species
(ROS). Even
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
low concentrations of isolated whey proteins are able to normalise the ROS
increase in
CACO2 (see Figure 15) caused by iron treatment highlighting the anti-oxidant
potential of
certain embodiments of the composition, which can be of benefit if the
formulation contains
ferrous iron.
In-vivo performance of ST1406 (dried, amorphous iron-protein bead with iron in
predominantly Fe2+ state) a wet gel iron-protein bead composition and a
solution of
ferrous sulfate in acidified water.
As shown in Figure 7, the in vivo performance of ST1406 was superior to the
wet-gel
formulation ST1404 which was made in the same manner as ST1406, but stored in
a sealed
container before drying. During this process, the iron largely oxidized over a
period of hours
and the release of fe2+ was reduced in comparison with ST1406 dried amorphous
microbeads of the invention. Iron absorption from the dried, amorphous iron-
protein
formulation (ST1406 with iron predominantly in the Fe2+ state), but not the
wet gel iron-
protein bead formulation, were superior to the market leading ferrous sulfate
solution.
Finally, the performance of the dried, amorphous ST1406 iron-protein
microbeads of
the invention was compared in subjects with higher and lower iron stores
measured by
serum ferritin levels and the results are depicted in Figure 8. This may
suggest that the iron
absorbed from the amorphous iron dried protein bead is absorbed via the DMT1
because its
activity is inversely related to ferritin stores.
Example 12: Stability Testing
It is important to note that intermediate gel beads are not stable with
respect to
oxidation and this is reflected in reduced release of ferrous iron (II) in
dissolution media. In
accordance with this, gel beads prepared for more than 24 hours have variable
and poor
performance clinically and are not scalable or commercially acceptable.
Furthermore, these
gel intermediates are prone to microbiological growth. ST1406 microbeads of
the invention
were found to be stable in that the dissolution profile at pH 1.6 and pH 6.6
was substantially
unchanged with respect to iron II release for at least 6 months when stored in
a sealed
container at ambient conditions. For example, in one embodiment of the
invention, when
blister packed in a [1] hydroxyl propyl methyl cellulose (HPMC) capsule under
ambient
conditions and in a [2] HPMC capsule under Nitrogen in a sealed chamber at
room
temperature, the composition released 97.8% 3.5% and 100.4% 2.9% of the
iron ll
content released at baseline (set at 100%) over 1 hour during dissolution
experiments at pH
6.6 following long term storage. Furthermore, both compositions were free of
objectionable
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
46
microorganisms, including a Total Viable Count with a Maximum Tolerable amount
of 103
cfu/1000mg, Total Yeast and Moulds Maximum Tolerable 102 cfu/1000mg, and E-
Coli
Absent.
Example 13: Preparation of ST1406 25 mg Iron Capsule for testing versus
Tardyferon 80mg.
Following protein heat denaturation the solution of aggregates was rapidly
cooled to
room temperature using constant agitation and then kept for 14 hours at 4 C
constantly
agitated. Using the DTNB Thiol testing according to Ellmann's reaction (El!man
GL (1959).
"Tissue sulfhydryl groups". Arch. Biochem. Biophys. 82 (1): 70-7.
doi:10.1016/0003-
9861(59)90090-6) the protein was sufficiently denatured following 45 minutes
heating at
80 C. The resulting whey protein oligomer solution was extruded through a
multinozzle
plate into a curing solution maintained at 65 C, (4M at pH 3.2), containing
ferrous sulfate
0.5M. Spherical microbeads were as described above in Example 1 and were
washed with
equal volumes of sterile, ultrapure water before drying in a fluidized bed
dryer under
nitrogen at 80 C inlet temperature. The resulting dry microbeads had an iron
concentration
of 4.5% and were hand filled into HPMC capsuled to give a final dose of 25mg
elemental
iron.
Figure 17 shows the serum iron concentration of Tardyferon 80 mg and 5T1406 25
mg following ingestion in fasting subjects (n=3) and cross-over to the
alternative
formulation. Tardyferon 80 mg is the trade name for a prolonged-release coated
tablet
containing ferrous sulfate. 5T1406 25 mg was prepared according to Example 13.
Figure 17
shows that 25 mg 5T1406 Iron caused a higher serum iron concentration than a
3x dose
Tardyferon, a marketed ferrous sulfate formulation claiming gastroprotection,
good
tolerability and equivalent efficacy to immediate release formulations of
ferrous sulfate.
Example 14: Preparation of 1.3% iron microspheres
Microspheres were made according to Example 1. After production the product
was
separated from the curing solution using a sieve and was washed with three
volumes (equal
to the volume of the beads after removal of curing solution) of ultrapure
sterile water to
yield microspheres containing about 1.3% iron after drying. Through
observation, the
microspheres were mono-dispersed, spherical and of equal size and shape and
appeared to
possess a skin on the outer surface. The bioavailability was much higher than
comparable
solutions of powdered ferrous sulfate and the microspheres demonstrated good
palatability
and tolerability, as shown in Figures 2 and 3.
CA 02961430 2017-03-15
WO 2016/041995
PCT/EP2015/071141
47
Example 15: Preparation of 2.5% or 4% iron microspheres
Microspheres were made according to Example 1. However the product was
washed with two equal volumes of ultrapure sterile water to yield microspheres
containing
about 2.5% or about 4% iron after drying. 300 mg microspheres are put into a
size zero
capsule to give a 7-9 mg dose. These microspheres were administered to
patients and
provided superior clinical efficacy to equimolar ferrous sulfate and also to
wet gel beads of
the formulation (Figure 7).
Example 16: Preparation of 5% or 6% iron microspheres
Microspheres were made according to Example 1. However the product was
washed with one equal volume of ultrapure sterile water. The microspheres were
formulated into a 25 mg elemental iron equivalent in a HPMC capsule and had,
for example
a relative bioavailability superior to that of Tardyferon, a marketed
formulation of ferrous
sulfate with 80mg elemental iron equivalents. (Figure 17).
Example 17: Preparation of 2.5% or 4% iron microspheres using 1-ascorbic acid
Microspheres were made according to Example 1. However the product was cured
in the curing solution additionally containing 100 mM L-ascorbic acid to
reduce oxidation of
the iron II. After production the product was separated from the curing
solution using a
sieve and was washed with two equal volumes of ultrapure sterile water to
yield
microspheres containing about 2.5% or 4% iron after drying.
Example 18: Preparation of zinc sulfate microspheres
Microspheres were made according to Example 1, however zinc heptahydrate
sulfate was
substituted for iron sulfate heptahydrate in the curing solution and had a
resultant pH of 3.8.
The produced microspheres were cured for 30 minutes in the curing solution.
The product
was separated from the curing solution using a sieve and was washed with two
volumes of
ultrapure sterile water to yield microspheres which were mono-dispersed,
spherical and of
equal size and shape. The microspheres demonstrated good palatability and
tolerability. The
resulting microspheres had a bland taste, making them highly palatable. In
contrast, an
acidified solution of zinc sulfate had poor palatability.
